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1. Introduction 
 
1.1. Peripheral opioid-mediated analgesia 
 
Current pharmacological treatment of severe acute (e.g. postoperative) and chronic 
(e.g. associated with cancer) clinical pain is based on two drug classes. One of them 
includes non-steroidal anti-inflammatory drugs (NSAIDs) such as paracetamol and ibuprofen, 
which are also used in rheumatoid arthritis. Although these drugs can provide some pain 
relief they are not very strong analgesics and produce severe side effects such as 
gastrointestinal ulcers and bleeding, thromboembolic complications, kidney and liver toxicity. 
The second class consists of opioids such as morphine, fentanyl and methadone, which are 
the most potent and efficacious drugs for postoperative and cancer pain. However, their use 
is limited by adverse effects such as nausea, respiratory depression, analgesic tolerance, 
physical dependence and addiction, which result from activation of opioid receptors in the 
central nervous system (CNS), mostly in the brain. Opioid receptors are not restricted to the 
CNS but they are also present on peripheral sensory nerves. The advantage of activation of 
such peripheral opioid receptors is pain inhibition (analgesia or antinociception) without CNS-
mediated side effects. The synthesis, signaling and analgesia upon activation of peripheral 
opioid receptors have been extensively examined in animal and clinical studies (reviewed in 
Stein et al., 2003; Machelska, 2007). 
To mimic clinical inflammatory pain, many animal studies used complete Freund`s 
adjuvant (CFA)-induced inflammation. CFA is a suspension of heat-inactivated mycobacteria 
(Mycobacterium butyricum or Mycobacterium tuberculosis) in mineral oil. Injection of CFA 
into a rat hind paw results in a localized inflammation characterized by paw swelling, 
redness, increased temperature and enhanced sensitivity to noxious mechanical and heat 
stimuli. Within 4 - 6 days the inflammation and pain are restricted to the inoculated paw. The 
contralateral paw remains non-inflamed and shows no difference compared to intact paws of 
control animals (Stein et al., 1988). Inflammation leads to enhanced synthesis of all three 
opioid receptor types (µ, δ, κ) in dorsal root ganglia (DRG) and to intra-axonal transport 
resulting in their augmented expression in peripheral terminals of sensory neurons. After 
agonist binding, neuronal opioid receptors couple to inhibitory G-proteins (Gi/o) which leads to 
inhibition of calcium and sodium channels, and of adenylyl cyclase followed by decreased 
levels of cyclic adenosine monophosphate. These events are augmented in peripheral 
inflamed tissue and result in decreased neuronal excitability and analgesia in animals and in 
humans (reviewed in Stein et al., 2003; Machelska, 2007). In rodent models, injection of 
systemically inactive doses of µ-, δ- and κ-opioid receptor agonists into inflamed tissues  
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produced dose-dependent antinociception, which was reversible with opioid receptor 
antagonists. Similar effects were found following systemic (e.g. subcutaneous [s.c.] or 
intraperitoneal [i.p.]) administration of opioids with limited access to the CNS (reviewed in 
Sawynok, 2003; Stein et al., 2003; DeHaven-Hudkins et al., 2004; Ossipov et al., 2004; 
Smith, 2008). Peripherally mediated opioid analgesic effects were confirmed in numerous 
clinical studies. In patients with acute or chronic knee inflammation (e.g. after joint surgery or 
in arthritis), intraarticular injection of small, peripherally selective doses of morphine has been 
shown to reduce pain (reviewed in Kalso et al., 2002; Sawynok et al., 2003; Stein et al., 
1991; Smith, 2008). In addition, such effects can be exerted by endogenous opioid peptides 
released by immune cells infiltrating inflamed tissues in animals and in patients (see 1.2, 1.3 
and 1.4).  
 
 
1.2. Opioid peptides in immune cells 
 
 Three families of endogenous opioid peptides, the endorphins (e.g. β-endorphin; 
END), enkephalins (e.g. Methionine-enkephalin [MENK] and Leucine-enkephalin [LENK]) 
and dynorphins (e.g. dynorphin A 1-17; DYN) were first characterized in the CNS. These 
peptides derive from the three respective precursor proteins proopiomelanocortin, 
proenkephalin and prodynorphin. All these opioid peptides share the N-terminal amino acid 
sequence Tyr-Gly-Gly-Phe-Met/Leu and show different affinity and selectivity for the three 
opioid receptors, µ (endorphins), δ (enkephalin) and κ (dynorphins). The endomorphins 
represent an additional group but their precursor(s) have not been identified so far (reviewed 
in Machelska, 2007). Within the CNS opioid peptides and their precursors are localized in 
structures involved in pain transmission such as thalamus, periaqueductal grey, reticular 
nuclei of the brainstem and dorsal horns of the spinal cord. Also peripheral sensory neurons 
express opioids. MENK, LENK and DYN, but not END, have been found in peripheral 
unmyelinated sensory axons, so called nociceptors, which specifically transmit nociceptive 
stimuli (Hassan et al., 1992; Carlton et al., 1997; Wu et al., 2005). Further, viral-driven 
delivery of MENK led to enhanced levels of the peptide in peripheral sensory neurons 
(Antunes bras et al., 2001) and produced antinociception in animal models of neuropathic 
and inflammatory pain (reviewed in Cope and Lariviere, 2006).  
Opioid peptides are also abundant in cells of the immune system. Under inflammatory 
conditions opioid peptide-containing circulating leukocytes extravasate using adhesion 
molecules (selectins, intercellular adhesion molecule-1, integrins α4 and β2) and chemokines 
(CXCL1, CXCL2/3) (Fig. 1.1). Thus, the selective blockade of these adhesion molecules or  
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chemokines substantially decreased the number of opioid-containing immune cells 
accumulating in inflamed tissue (Machelska et al., 1998, 2002, 2004; Brack et al., 2004b) 
and in consequence abolished endogenous peripheral opioid analgesia (see paragraph 1.4).  
In accord with the extravasation of opioid-containing cells, mRNA of proopiomelanocortin, 
proenkephalin and prodynorphin as well as END, MENK, LENK and DYN are detected in 
leukocytes accumulating in inflamed tissues in animals (Stein et al, 1990b; Przewlocki et al., 
1992; Hassan et al., 1992; Mousa et al., 2004). In early stages of CFA-induced paw 
inflammation (6 h) the major subpopulation of opioid-containing cells are granulocytes, 
whereas later (4 days) monocytes and macrophages dominate with some infiltration of T 
lymphocytes (Mousa et al., 2001; Rittner et al., 2001). During this course of inflammation the 
leukocytic content of opioids and the number of opioid-containing leukocytes increase 
(Rittner et al., 2001) and proopiomelanocortin mRNA and END are up-regulated in cells of 
lymph nodes draining the inflamed tissue (Cabot et al., 1997; Sitte et al., 2007). Furthermore, 
END and MENK were detected in synovial granulocytes, macrophages/monocytes, 
lymphocytes and plasma cells in patients with acute knee trauma or arthritis (Mousa et al., 
2007). Together, these findings provide strong evidence on the presence of opioid peptides 




1.3. Secretion of opioid peptides by leukocytes 
 
To exert their effects opioid peptides need to be secreted. In extensive in vitro studies 
it has been shown that basal release of MENK, DYN and END from lymphocytes can be 
stimulated with corticotropin-releasing factor (CRF), interleukin-1β (IL-1) and noradrenaline. 
This secretion was CRF-, IL-1- and adrenergic-receptor specific, respectively, and it was 
calcium dependent and mimicked by potassium, consistent with vesicular release (Schäfer et 
al., 1994; Cabot et al., 1997, 2001; Binder et al., 2004) (Fig. 1.1). Further, chemokines acting 
at CXCR1/2 receptors induced MENK and END release from human and rat granulocytes, 
which was dependent on inositol triphosphate receptor-triggered release of calcium from 
endoplasmic reticulum and (partially) on phosphinositol-3-kinase (Rittner et al., 2006). Also, 
immersion of non-inflamed rat hind paws in hot water resulted in increased MENK and LENK 
levels in the perfusate. It was suggested that opioids originated mainly from resident immune 
and Merkel cells, although this was not directly investigated (Yonehara et al., 1993).  
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Figure 1.1. Migration of opioid-containing immune cells and opioid peptide secretion within inflamed 
tissue. During inflammation P-selectin, intercellular adhesion molecule-1 (ICAM-1) and platelet-
endothelial cell adhesion molecule-1 (PECAM-1) are up-regulated on vascular endothelium, while L-
selectin, integrins α4 and β2 are expressed on opioid-containing immune cells. This results in the 
migration of opioid-containing leukocytes through the blood vessel endothelium into the extravascular 
space of the inflamed tissue. In response to environmental stress or to agents such as chemokines 
CXCL1 and CXCL2/3, corticotropin-releasing factor (CRF) and interleukin (IL)-1 immune cells release 
opioid peptides. Chemokines, CRF and IL-1 act at chemokine receptors, CRF receptors (CRFR) and 
IL-1 receptors (IL-1R), respectively, which are expressed on opioid-containing leukocytes. Secreted 
opioid peptides bind to peripheral opioid receptors (produced in dorsal root ganglia and transported to 
peripheral endings of sensory neurons) and reduce inflammatory pain. Modified from Stein et al., 2003 
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1.4. Analgesic effects of immune cell-derived opioids 
 
Stress is a natural stimulus triggering inhibition of pain. In rats with unilateral hind paw 
inflammation induced with CFA, exposure to cold (4°C) water swim stress strongly inhibited 
sensitivity to noxious mechanical stimuli (paw pressure) exclusively in inflamed paws. This 
antinociceptive effect was dose-dependently reversible by antibodies (Abs) against opioid 
peptides and by opioid receptor antagonists injected into the plantar surface (intraplantarly; 
i.pl.) of inflamed paws (Parsons et al., 1990; Stein et al., 1990a, 1990b; Przewlocki et al., 
1992). Leukocytes are the source of opioid peptides because antinociception was 
substantially reduced by immunosuppression with cyclosporine A or whole body irradiation, 
by depletion of granulocytes or of monocytes/macrophages, by blocking the extravasation of 
immune cells following inhibition of L- and P-selectins, integrins (α4 and β2) or intercellular 
adhesion molecule-1 (Stein et al., 1990b; Przewlocki et al., 1992; Machelska et al., 1998, 
2002, 2004; Brack et al., 2004a). CRF, IL-1, noradrenaline and CXCL2/3 chemokine injected 
into inflamed paws produced opioid-mediated antinociception, reversible by i.pl. pretreatment 
with selective antagonists of CRF-, IL-1-, adrenergic (α1, α2 and β2)- and opioid-receptors or 
by Abs against END, MENK or DYN (Schäfer et al., 1994, 1996; Machelska et al., 2003; 
Binder et al., 2004; Ritttner et al., 2006). Furthermore, we recently showed that leukocyte-
derived opioids are also essential regulators of pain resulting from injury to peripheral nerves 
i.e. neuropathic pain. In a mouse model of sciatic nerve injury we found that immune cells 
containing MENK, DYN and END accumulate at the site of nerve damage and that their 
activation by CRF effectively suppressed pain (Labuz et al., 2009). Also, genetic absence of 
T lymphocytes expressing END reduced CRF-induced antinociception, which was fully 
restored by transfer of wild-type mice-derived T lymphocytes (Labuz et al., 2010). 
Importantly, peripheral endogenous mechanisms of opioid analgesia are clinically relevant. In 
patients undergoing knee surgery blockade of opioid receptors by the antagonist naloxone 
injected into the knee joint infiltrated by opioid peptide-containing leukocytes resulted in 
increased postoperative pain (Stein et al., 1993; Mousa et al., 2007). This suggests that opioids 
are tonically released and activate peripheral opioid receptors in inflamed tissue to attenuate 
clinical pain. Furthermore, the intraarticular injection of CRF produced a transient but 
significant reduction of postoperative pain, apparently by releasing opioid peptides from 
synovial inflammatory cells (Likar et al., 2007). 
 Together, these findings clearly show that immune cell-derived opioid peptides act at 
peripheral opioid receptors directly in injured peripheral tissues to decrease pain associated 
with inflammation or nerve damage in animals and humans. However, the antinociceptive 
effects after swim stress or injection of IL-1 and CRF were relatively short-lasting in animal 
____________________________________________________________________________________________________________
 Introduction 
  13 
 
models and in patients (10 – 30 min) (Stein et al., 1990a; Schäfer et al., 1994; Likar et al., 




1.5. Peptidases degrading opioid peptides  
 
Among peptidases localized on the surface of neurons and immune cells, the best 
characterized enzymes inactivating opioid peptides are aminopeptidase N (APN or CD13; 
EC 3.4.11.2) and neutral endopeptidase (NEP or CD10; EC 3.4.24.11), which belong to the 
family of zinc metallopeptidases. They are type II integral membrane proteins with a short 
cytoplasmic region, a transmembrane region and a large extracellular C-terminus. Their 
active sites are characterized by a zinc atom, which is incorporated into two histidine 
residues in the consensus sequence HExxH. The glutamate in this sequence transfers a 
hydrogen atom and activates the nucleophilic attack of the polarized zinc-bound water on the 
peptide bond. The specificity of the active site is essentially ensured by Van der Waals and 
ionic interactions between the S2, S1, S1`, and S2`subunits and the lateral chain of the 
corresponding P2, P1, P1` and P2` moieties of the substrate (Roques et al., 1993; Tiraboschi 
et al., 1999).  
 
 
1.5.1. APN expression and function 
 
APN is a 130 - 160 kDa glycoprotein widely distributed in most mammalian tissues 
such as kidney, intenstine, liver, lung, fibroblasts and vessels. APN is also expressed in 
several immune cell types such as monocytes, macrophages, granulocytes and dendritic 
cells (Watt et al., 1989; Shipp and Look, 1993; Jardinaud et al., 2004; Mina-Osorio, 2008). T- 
and B- lymphocytes in earliest stage of differentiation are APN-positive but become APN-
negative upon maturation. Thus, lymphocytes in blood, spleen and tonsils were APN-
negative (Riemann et al., 1999); however they expressed the enzyme in synovial fluid of 
rheumatoid arthritis patients (Riemann et al., 1993). In the brain APN was found in 
endothelial cells of microvessels, cerebral membranes and meninges (Gros et al., 1985; 
Solhonne et al., 1987; Noble et al., 2001). In the pig peripheral nervous system APN is 
associated with peripheral nerve microvessels and connective tissues including perineurium 
(Barnes et al., 1991).  
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APN belongs to exopeptidases because it removes N-terminal amino acids of 
peptides. It is a multifunctional protein involved in invasion and metastasis of cancer cells 
(Hashida et al., 2002), viral infection (Kolb et al. 1998), signal transduction (Mina-Osorio et 
al., 2006) and chemotaxis (Proost et al., 2007; Wulfaenger et al., 2008). The main function of 
APN is the degradation of peptides including the opioids MENK and LENK (Fig. 1.2) but also 
neurokinin A, somatostatin, vasoactive peptides (angiotensin III, lysyl-bradykinin), 
chemokines (e.g. CXCL8, CXCL11/12) and immunomodulating peptides (Miller et al., 1994a, 





Figure 1.2. Schematic representation of interaction of LENK or MENK with the active site of APN. 
Adapted from Chen et al. (2000).  
 
 
1.5.2.  NEP expression and function 
 
NEP belongs to a family of mammalian zinc metallopeptidases, which also include 
endothelin-converting enzymes (ECE), the erythrocyte surface antigen KELL, the phosphate-
regulating gene on the X chromosome and recently identified damage-induced neuronal 
endopeptidase. NEP is a 90 - 110 kDa glycoprotein widely distributed on mammalian cells in 
kidney, brain, spinal cord, placenta, testes, ovaries, adrenal cortex, granulocytes, 
macrophages, pre-B lymphocytes, circulating and synovial T lymphocytes (Shipp and Look, 
1993; Turner et al., 1997; Oefner et al., 2004; Simonini et al., 2005; Schroeter et al., 2007). 
In the pig and rat peripheral nervous system, NEP is located in Schwann cell membranes 
surrounding the DRG and in unmyelinated nerve fibers (Matsas et al., 1986; Kioussi et al., 
1992).   
NEP expressed on surface of neutrophils plays a role as tumor-associated antigen, it 
is known as common acute lymphoblastic leukemia antigen and can also act as a receptor of  
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the human immunodeficiency virus 1 (Roques et al., 1993). NEP belongs to endopeptidases, 
acting on the amino terminus of hydrophobic amino acid residues in a peptide chain. It is 
important in terminating the activity of peptides involved in cardiovascular functions (artrial 
natriuretic factor, bradykinin), inflammation (substance P, IL-1, angiotensin II), synaptic 
neuropeptide metabolism (neurotensin, cholecystokinin-8) and chemotaxis (fMet-Leu-Phe). 
Regarding opioid peptides, NEP degrades predominantly enkephalins (LENK and MENK) by 
cleaving their glycin-phenyl (Gly3 – Phe4) bond (Fig. 1.3), but a few reports also described 






Figure 1.3. Schematic representation of interaction of LENK or MENK with the active site of NEP. 
Adapted from Chen et al. (2000).  
 
 
1.6. APN and NEP inhibitors 
 
1.6.1. Bestatin – APN inhibitor 
 
Bestatin (C16H24N2O4) is a potent peptidase inhibitor discovered in filtrates of 
Streptomyces olivoreticuli cultures in Japan 25 years ago. It is a natural analog of the 
dipeptide Phe-Leu with a secondary alcohol inserted between the two amino acids (Fig. 1.4). 
In addition to blocking APN, bestatin can also bind to other metallopeptidases such as  
leucyl-, alanyl- and cystinyl-aminopeptidases. The inhibitor-enzyme complex is tight and 
bestatin exhibits competitive kinetics with the peptidase substrates (Scornik et al., 2001).  
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Figure 1.4. Binding of bestatin to the active site of APN. Adapted from Bauvois and Dauzonne (2006). 
 
 
1.6.2. Thiorphan – NEP inhibitor 
 
In 1980 the group of Bernard Roques developed the synthetic selective NEP inhibitor 
thiorphan (C12H15NO3S). This inhibitor contains a thiol group, which interacts with the zinc 
atom in the active NEP site (Fig. 1.5) with high inhibitory potency in the nanomolar range 









Figure 1.5. Thiorphan interacting with the active site of NEP. Adapted from Roques et al. (1980). 
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1.6.3. Dual inhibitors blocking APN and NEP simultaneously  
 
It has been shown that simultaneous blockade of APN and NEP was more effective 
than their separate inhibition in elevating extracellular MENK levels in the CNS and in 
producing antinociception (see paragraph 1.7). This led to the development of dual inhibitors 
that block both enzymes concurrently. Dual inhibitors have the additional advantage of 
avoiding different pharmacokinetics and bioavailability when two “single” inhibitors are 
employed (Chen et al., 1998). The most extensively studied dual inhibitors are kelatorphan 
and RB101 (Fournie-Zaluski et al., 1984, 1992). However, the affinities of these compounds 
for APN are up to 100-fold lower than for NEP (Chen et al., 1998). To improve the potency of 
inhibiting both peptidases with similar affinities, new aminophosphinic compounds were 
designed. Their general formula NH2-CH(R1)P(O)_(OH)CH2-CH(R2)CONH_CH(R3)COOH 
contains a phosphinic moiety as a zinc coordinating ligand. The side chains R1 = Ph, R2 = 
CH2Ph(p-Ph), R3 = CH3 are responsible for optimal recognition of APN and NEP in the 
nanomolar range. It was found out that a small residue on R3 optimized the recognition of 
NEP subsites and a free N-terminal amino group for optimal APN binding (Chen et al., 1998, 
2000). One of the newest is P8B, synthesized by our collaborator Prof. B. Roques (Université 
Paris). P8B came out as the most promising phosphinic inhibitor blocking the activities of 
NEP (Ki = 2.0 nM) and of APN (Ki = 4.8 nM) in the nanomolar range in vitro combined with 







Figure 1.6. Binding of a dual inhibitor to the active site of APN/NEP. Adapted from Chen et al. (2001) 
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1.7. Effects of peptidase inhibitors on opioid peptide levels and pain  
 
The actions of secreted opioid peptides can be enhanced and prolonged when their 
degrading enzymes are inhibited. Bestatin and thiorphan have been shown to block 
H3[MENK] and H3[LENK] degradation in rat and mouse brain slices and in rat spinal cord 
slices. Administration into cerebral ventricles (intracerebroventrically; i.c.v.) of bestatin or 
thiorphan resulted in a reduction of H3[MENK] hydrolysis product levels in rat brain in vivo 
(Roques et al., 1980; De la Baume et al., 1983; Challet et al., 1983; Bourgoin et al., 1986; 
Giros et al., 1986b). These effects on enkephalin levels were associated with antinociceptive 
actions, which were mostly studied in healthy animals with no pathological pain. Bestatin 
potentiated antinociception induced by intracerebrally administered dynorphins in mice 
(Nakazawa et al., 1989). Intrathecal bestatin or thiorphan potentiated antinociception and 
increased the amount of MENK released in the spinal cord in response to i.c.v. END in rats 
(Suh et al., 1990). In rats bestatin or thiorphan potentiated antinociception induced by 
intrathecal END and increased the amount of MENK released from spinal cord (Suh et al., 
1990). The i.c.v. application of thiorphan produced antinociception after thermal noxious 
stimulation, which was blocked by the opioid receptor antagonist naloxone (Roques et al., 
1980; De la Baume et al., 1983). Further studies showed that simultaneous blockade of NEP 
and APN by a combination of bestatin and thiorphan was more efficient in enhancing the 
extracellular MENK concentrations compared with the separate inhibition of each peptidase 
(Bourgoin et al., 1986; De la Baume et al., 1983). Also, the simultaneous injection of bestatin 
and thiorphan elicited opioid receptor-mediated antinociceptive effects after thermal 
stimulation in healthy mice (Carenzi et al., 1983). In a model of pathological pain, the 
combined injection of bestatin and thiorphan into inflamed paws enhanced opioid 
antinociception induced by swim stress (Parsons and Herz, 1990). These findings also have 
clinical relevance. In arthritic patients NEP was found in plasma, synovial fluid, 
polymorphonuclear cells and lymphocytes (Appelboom et al., 1991; Matucci-Cerinic et al., 
1993; Simonini et al., 2005), and APN was expressed on T cells in synovial tissue (Riemann 
et al., 1993). Intravenous injections of thiorphan or its prodrug acetorphan decreased NEP 
activity in plasma and cerebrospinal fluid and produced some analgesia in a small number of 
patients with migraine or after myelography (Floras et al., 1983; Spillantini et al., 1986). In 
accord with animal studies, thiorphan and bestatin produced stronger pain inhibition when 
applied together in cancer patients (Meynadier et al., 1988)  
 Following the concomitant use of selective APN and NEP inhibitors the actions of 
dual peptidase inhibitors were tested (see also paragraph 1.6.3). The antinociceptive action 
of i.c.v. MENK was potentiated by co-administration of kelatorphan. This effect was even 
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higher than that produced by a combination of bestatin and thiorphan (Fournie-Zaluski et 
al.,1984). RB101 administered systemically elevated extracellular levels of MENK-like 
material in the nucleus accumbens of rats (Daugé et al., 1996) and induced opioid 
antinociception after thermal, mechanical and chemical noxious stimuli in healthy animals 
(Noble et al., 1992). In CFA-induced paw inflammation RB101 injected i.v. produced opioid 
antinociception after mechanical noxious stimulation (Maldonado et al., 1994). A new dual 
aminophosphinic inhibitor RB3007 increased extracellular levels of endogenous MENK in the 
periaqueductal grey of rats. In mice, i.v. injection of this inhibitor decreased sensitivity to 
thermal and mechanical stimuli as well as formalin-induced tonic pain and produced longer-
lasting antinociception compared with RB101. In CFA inflammatory pain model i.v. injection 
of RB3007 led to antinociception in inflamed and non-inflamed rat hind paws (Le Guen et al, 
2003). Also, i.c.v. injected P8B produced opioid antinociception against thermal noxious 
stimulation in healthy mice (Chen et al., 1998, 2000). In none of these studies END or DYN 
have been examined directly, possibly because of earlier findings that ENKs were the 
preferred substrates of NEP and APN (Matsas et al., 1983; Hersh, 1984). However, one 
study reported degradation of END to gamma-END by NEP (Graf et al., 1985) and there are 
reports on the cleavage of DYN by APN and NEP, which could be prevented by their 
inhibitors (Safavi and Hersh, 1995; Song and Marvizon, 2003).  
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1.8. Hypothesis and objectives 
 
 Currently used pain medications have major side effects such as gastrointestinal 
ulcers, tolerance or addiction. Effective analgesia without adverse effects can be achieved by 
exogenously applied or endogenous opioids activating opioid receptors on peripheral 
sensory neurons. Because opioid peptides are susceptible to enzymatic inactivation their 
analgesic actions might be enhanced by inhibiting their degradation. Previous studies 
suggested that blockade of APN and NEP activity prevents the catabolism of enkephalins 
and leads to antinociception, but effects on END or DYN have not been examined directly. 
So far, these studies concerned the CNS, mostly in animal models without or only short-
lasting tissue injury, and they did not examine specific cellular sources of peptidases.  
 In the current studies we hypothesized that blocking the opioid-metabolizing 
peptidases APN and NEP expressed in immune cells or in nerves in peripheral inflamed 
tissue will prevent opioid peptide degradation leading to the local inhibition of pain. To 
inactivate peptidases we used classical selective inhibitors of APN (bestatin) and of NEP 
(thiorphan) as well as a novel dual inhibitor P8B. As a model of pathological pain we 
employed CFA-induced unilateral hind paw inflammation in rats. We used cell biological (flow 
cytometry) and biochemical (photospectrometry, radioimmunoassay) as well as in vivo pain 
testing methods. The main goals were: 
a) To characterize and quantify leukocyte subpopulations expressing APN and NEP in 
inflamed tissue 
b) To verify the activities of leukocytic APN and NEP using their selective synthetic 
substrates  
c) To quantify the activities of neuronal APN and NEP using their selective synthetic 
substrates in peripheral nerves innervating inflamed and non-inflamed tissue 
d) To examine the degradation of the four opioid peptides MENK, LENK, DYN and END, 
and to investigate which of them can be prevented from catabolism by leukocytic and 
neuronal APN and NEP by using selective and dual inhibitors  
e) To validate the antinociceptive effects induced by APN- and NEP-inhibitors in 
peripheral inflamed tissue in vivo  
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2. Animals, Materials and Methods 
 
2.1. Animals and animal housing 
 
Male Wistar rats (250 - 300 g) were housed in pairs in cages lined with the standard 
bedding in a 12 h light-dark (8 a.m. /8 p.m.) cycle with food pellets and water ad libitum. 
Room temperature was maintained at 22 ± 0.5°C and at a relative humidity between 40% 
and 60%. Experiments were approved by the local animal committee (Landesamt für 
Gesundheit und Soziales Berlin, Germany) and performed in accordance with ethical 





Materials are listed in alphabetical order and the distributors`names are given. For 





Table 2.1: Antibodies used for the following applications: F = flow cytometry, RIA = 
radioimmunoassay. Other abbreviations: FITC = fluorescein isothiocyanate conjugated, PE = 
phycoerythrin conjugated, PE-Cy5 = PE-cytochrome 5 conjugated. 
Antibody Application Company 
Goat anti-rabbit IgG RIA Bachem 
Mouse anti-human, crossreacting with rat CD10 
(SN5c)-FITC 
F Santa Cruz 
Mouse anti-human, crossreacting with rat CD13 
(WM15)-FITC 
F Santa Cruz 
Mouse anti-rat T lymphocytes (CD3; G4.18)-PE F Pharmingen 
Mouse anti-rat hematopoietic cells (CD45; OX-1)-
PE-Cy-Chrome 5 
F Pharmingen 
Mouse anti-rat macrophages (CD163; ED2)-PE F Serotec 
Mouse anti-rat granulocytes (RP-1)-PE F Pharmingen 
Normal rabbit serum RIA Bachem 
Rabbit anti-rat DYN  RIA Bachem 
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Antibody Application Company 
Rabbit anti-rat END RIA Phoenix Laboratories 
Rabbit anti-rat LENK RIA Bachem 
Rabbit anti-rat MENK RIA Bachem 
Rat anti-mouse IgG 1 κ-FITC (isotype control)  F Pharmingen 
Rat anti-mouse IgG 1-PE (isotype control)  F Pharmingen 
Rat anti-mouse IgG 2a κ-PE (isotype control) F Pharmingen 
Rat anti-mouse IgG 3 κ-PE (isotype control)  F Pharmingen 
 
 
2.2.2. Chemicals, kits and media 
 
Table 2.2: List of chemicals, kits and media 
ß-naphthylamine (ßNA) Sigma-Aldrich 
BD TrucountTM Tubes BD Biosciences 
Bestatin hydrochloride  Sigma-Aldrich 
Bovine serum albumin (BSA) Sigma-Aldrich 
Collagenase from Clostridium histolyticum Sigma-Aldrich 
Complete Freund`s adjuvant (CFA) Calbiochem 
Dimethyl sulfhoxid Hybri-MAX® (DMSO) Sigma-Aldrich 
Fast blue B (FBB) salt Sigma-Aldrich 






Isofluran (1-Chloro-2,2,2-trifluoroethyl-difluoronetylether) Abbott 
L-Alanin ß-naphthylamine (Ala-βNA) Sigma-Aldrich 
Paraformaldehyde (PFA) Sigma-Aldrich 
Penicillin/streptomycin (10,000U/10,000 µg/ml) Biochrom 
Phosphate buffered saline (PBS, 0.1 M, pH 7.4) GIBCO  Invitrogen 
P-nitroaniline (pNA) Sigma-Aldrich 
Rat-DYN RIA kit Bachem 
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Rat-END RIA kit Phoenix Laboratory 
Rat-LENK RIA kit Bachem 




RPMI-1640 medium Life Technologies 




Thiorphan  Sigma-Aldrich 
Tri(hydroxymethyl)-aminomethan (Tris) Sigma-Aldrich 
TrueCOUNT® Parmingen/Becton 
Trypan blue stain 0,4%  GIBCO  Invitrogen 
 
 
2.2.3. Equipment and other materials 
 
Table 2.3: List of equipment and other materials 
Cell strainer (70 µm mesh) BD Bioscience Discovery Labware 
Fluorescence activated cell sorting (FACS Calibur) Becton-Dickinson 
Gamma-counter, Wallac Wizard 1470 Wallac 
Heraeus incubator Kendro 
Microscope (Axiovert 25) Carl Zeiss Mikroskopie 
Orion PerpHecT ROSS micro combination 
pH electrode 
Thermo Electron Corporation 
Polyethylene tubes (15 and 50 ml) Falcon 
Paw pressure algesiometer  Ugo Basile 
Ultrapure water systems (Direct-QTM 5) Millipore 
Ultrasound-bath Sonorex RK 52H Bandelin 
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2.3.1. Anaesthesia  
 
Inhalational anaesthesia with isoflurane was used to perform all i.pl. injections and to 
kill the rats. This was done by placing an animal in a glass chamber on a perforated ceramic 
plate covering a tissue soaked with isoflurane. 
 
 
2.3.2. Induction of inflammation 
 
Rats received an i.pl. injection of 0.15 ml of CFA into the right hind paw under brief 
isoflurane anesthesia. This inflammatory model is routinely used in our as well as in other 
research groups (Stein et al., 1988; Barber and Gottschlich 1992). It is characterized by 
swelling, increased temperature and enhanced sensitivity to noxious pressure (hyperalgesia) 
in the CFA-inoculated paw. During the course of 4 days the inflammation and hyperalgesia 
remain confined to the CFA-injected paw and there are no significant differences in feeding 
behavior, body weight, body temperature and general activity compared to untreated animals 
(Stein et al., 1988). 
 
 
2.3.3. Measurement of pH value in subcutaneous paw tissue 
 
To measure pH in the paw and to prepare tissues for in vitro experiments (see below) 
rats were killed by isoflurane inhalation. Immediately afterwards the skin on the plantar 
surface of CFA-inflamed and contralateral non-inflamed paws was cut and a special pH 
electrode was inserted i.pl. through the incision to determine the pH. 
 
 
2.3.4. Tissue preparation 
 
2.3.4.1. Preparation of immune cell suspensions from inflamed paws 
 
Plantar subcutaneous tissue was dissected from inflamed rat hind paws and 
digested in a solution containing 30 mg collagenase, 10 mg hyaluronidase, and 0.5 ml 
HEPES per 10 ml RPMI buffer with 2% FBS for 1 h at 37°C, as previously 
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(Rittner et al., 2001). Cells were dissociated from homogenates using a 70 µm mesh cell 
strainer and suspended in RPMI medium. Cell number and viability (90 – 95%) was 
examined by the trypan blue exclusion method using a Neubauer chamber. Cells were 
reconstituted in RPMI at a concentration of 5 x 106 cells in 250 µl. They were either directly 
transferred for flow cytometry, for enzyme activity or opioid peptide RIA. 
 
 
2.3.4.2. Preparation of membranes from immune cells and kidney 
 
Kidneys and immune cells isolated from rat inflamed paws (see paragraph 2.3.4.1) 
were homogenized and centrifuged at 15,000 x g for 15 min at 4°C to obtain a granular pellet 
and supernatant containing cell membranes. The supernatant was centrifuged at 48,000 x g 
for 30 min at 4°C to obtain a solid membrane fracti on, according to Balog (1999). The 
membranes from 5 x 106 immune cells were reconstituted in 250 µl of RPMI, and those from 
kidneys in 2 ml of PBS per one kidney. 
 
 
2.3.4.2. Preparation of peripheral nerve suspensions 
 
The skin and muscles of the paw were cut and sciatic nerves terminal branches of 
the tibial, sural and common peroneal nerves innervating the plantar subcutaneous paw 
tissue were dissected. The nerve tissue was cut into small pieces placed in 300 µl RPMI 
buffer and homogenized using 10 x power 10% pulsed ultrasound. 
 
 
2.3.5. Flow cytometry 
 
Staining of leukocytes isolated from inflamed paws was performed as previously 
described (Rittner et al., 2001; Machelska et al., 2002). All centrifugations of cell suspensions 
were run for 5 min at room temperature and 450 x g using a swinging bucket rotor. 
Antibodies were conjugated with either fluorescein isothiocyanate (FITC), R-phycoerythrin 
(R-PE) or phycoerythrin-cytochrome 5 (PE-Cy5), as listed below, and were used in 2-color or 
3-color staining. A total of 50,000 – 90,000 events were measured per sample in a FACS 
Calibur apparatus. Data were analyzed using CellQuest software (Parmingen/Becton 
Dickinson). 
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  Staining of cell surface markers was performed first. Cells were suspended in 1 x 
PBS and centrifuged. Supernatants were softly decanted to leave 50 µl of buffer per sample. 
Single cell suspensions were stained for 15 min at room temperature without exposure to 
light with anti-CD45-PE-Cy5 (12 µg/ml) to identify hematopoietic cells, with mouse anti-
human (crossreacting with rat) CD13-FITC (10 µg/ml) to identify APN and with mouse anti-
human (crossreacting with rat) CD10-FITC (10 µg/ml) to identify NEP. T -lymphocytes were 
stained with mouse anti-rat CD3-R-PE (12 µg/ml) and macrophages with mouse anti-rat 
CD163-R-PE (5 µl/ 1 x 106 cells). Unbound Abs were removed by washing twice with PBS. 
 For intracellular staining cell suspensions were fixed for 30 min with PBS containing 
1% PFA and permeabilized in PBS containing 0.5% saponin and 0.5% BSA. After 
centrifugation cells were incubated for 30 min at room temperature with intracellular mouse 
anti-rat Ab recognizing granulocytes (RP-1-R-PE, 6 µg/ml).  
Specificity of the staining was verified by incubation of cell suspensions with 
appropriate isotype-matched rat anti-mouse IgGs (12 µg/ml). To calculate absolute numbers 
of cells per paw, the stained cell suspensions were analyzed together with a known number 
of fluorescent beads in a TruCOUNT® tube. Numbers of cells per tube were calculated in 
relation to the known number of fluorescence TruCOUNT® beads and extrapolated to the 
whole paw. To exclude non-hematopoietic cells, only CD45+ cells were analyzed.  
 
 
2.3.6. APN-induced degradation of its specific substrate 
 
APN activity was determined according to Balog et al. (1999) using Ala-βNA as a 
substrate. Immune cell suspensions (1.5 x 106 cells in 250 µl) were incubated with 200 µM of 
Ala-βNA in PBS (pH ranging from 5.0 – 8.0) for 4 h at 37°C in Heraeus incubator. Because 
there were no significant differences between pH conditions further experiments were 
performed at pH 7.4, as described previously (Florentin et al., 1984). Ala-βNA was freshly 
prepared as a stock solution in DMSO and diluted with 1:100 PBS immediately before use. 
Samples were incubated in PBS without or with bestatin (5 – 20 mM) or P8B (0.1 – 10 mM) 
and measured in duplicates. Rat kidney membranes (100 µl) were used as a positive and 
PBS as a negative control. After incubation, βNA was visualized in 0.5 ml of supernatant 
using 0.2 ml FBB solution (1.5 mg FBB dissolved in 1 ml PBS with 10% TWEEN-20 
detergent, pH 4.2).  
Similar experiments were performed with membranes from immune cells (prepared 
from 1.5 x 106 cells). Samples were incubated in PBS without or with bestatin (5 – 50 µM) or 
P8B (1 – 10 µM) and were measured in duplicates. Cleavage of Ala-βNA in immune cell  
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membranes and in whole immune cells was quantified photospectrometrically by absorbance 
at 530 nm compared to a standard curve of βNA and was expressed in µmol / 106 cells / 4 h.  
Suspensions of terminal nerve branches (50 µl) were incubated in PBS without or 
with bestatin (5 – 15 mM) or P8B (1 – 10 mM) and measured in duplicates. Rates of 
cleavage of Ala-βNA were measured in the supernatant (0.15 µl) and expressed in mmol / g 
tissue / 4 h. 
 
 
2.3.7. NEP-induced degradation of its specific substrate 
 
NEP activity was measured according to Balog et al. (2001) using Suc-Ala-Ala-Phe–
pNA as a substrate. Briefly, immune cells (2.5 x 106 cells) were prepared (see paragraph 
2.3.4.1) and suspended in PBS (pH ranging from 5.0 – 8.0). Because there were no 
significant differences between different pH conditions further experiments were performed at 
pH 7.4, similar to experiments with APN (see paragraph 2.3.6). Samples were incubated for 
4 h at 37°C in Heraeus incubator with 100 µM of Suc -Ala-Ala-Phe–pNA in PBS without or 
with thiorphan (8 – 10 mM) or P8B (0.1 – 10 mM) and were measured in duplicates. Rat 
kidney membranes (100 µl) were used as a positive and PBS as a negative control. After 
incubation the presence of pNA was measured photospectrometrically at 405 nm in the 
supernatant (0.5 ml), and concentrations were calculated from a standard curve. NEP activity 
was expressed as µmol / 106 cells / 4 h. 
Similar experiments were performed with immune cell membranes (prepared from 2.5 
x 106 cells). Samples were incubated in PBS without or with thiorphan (1 – 10 µM) or P8B (1 
– 10 µM) and measured in duplicates. To assess whether peptidase inhibitors interfere with 
photospectrometric measurements, bestatin (0.5 – 15 mM) and thiorphan (0.1 – 10 mM) or 
P8B (0.1 – 10 mM) without APN and NEP substrates were also tested. 
Suspensions of nerve terminal branches (50 µl) were incubated in PBS without or 
with thiorphan (5 – 8 mM) or P8B (1 – 10 mM) and measured in duplicates. Metabolite pNA 
was quantified in the supernatant (0.15 µl) and expressed in mmol / g tissue / 4 h. 
 
 
2.3.8. APN- and NEP-induced degradation of opioid peptides 
 
Freshly prepared suspensions of vital immune cells were incubated in 250 µl RPMI 
buffer without or with a combination of bestatin (5 mM) and thiorphan (1 mM) or with P8B (5 
mM). The samples (in a total volume of 500 µl) were centrifuged at 760 x g for 5 min at 4°C 
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either immediately after addition of peptidase inhibitors (basal measurements) or after 4, 6 or 
8 h of incubation. Afterwards the supernatants (400 µl) were collected and stored at –20°C 
until RIA measurements. Each experiment was repeated 3 - 4 times.  
Freshly prepared suspensions of immune cell membranes (250 µl) or nerve terminals 
(50 µl) were incubated in 150 µl RPMI buffer without or with a combination of bestatin (5 µM 
– 10 mM) and thiorphan (1 µM – 5 mM) or with P8B (1 µM – 10 mM). After 15 min of 
preincubation at 37°C in Heraeus incubator 100 µl o f the standard opioid peptide MENK 
(12.8 ng/ml), LENK, DYN or END (each at 1.28 ng/ml) was added, obtaining a total volume 
of 500 µl for immune cell membranes or of 300 µl for nerves. The samples were centrifuged 
for 5 min at 760 x g and 4°C either immediately after addition of opioi d peptides (basal 
measurements) or after 4 h of incubation with the tissues and peptidase inhibitors. 
Subsequently, the supernatants were collected and stored at –20°C until RIA. Each 
experiment was repeated 3 - 8 times. 
 
 
2.3.9. Measurement of opioid peptide concentrations by RIA  
 
RIA was performed according to Cabot et al. (1997, 2001) and Binder et al. (2004). 
Supernatants (see paragraph 2.3.8) were thawed and analyzed for the content of MENK, 
LENK, DYN or END using commercially available RIA kits. Reaction tubes containing 100 µl 
of the respective standard opioid peptide concentrations or unknown samples were prepared 
in duplicates. They were incubated overnight at 4°C  with 100 µl of primary Ab against the 
respective opioid peptide. On the second day, 100 µl of I-125-labeled opioid peptide tracer 
(10,000 – 12,000 cpm) was added and tubes were incubated overnight at 4°C. On the third 
day, 100 µl of goat anti-rabbit IgG and 100 µl of normal rabbit serum were added followed by 
incubation for 90 min at room temperature. Subsequently, 500 µl RIA buffer was added and 
tubes were centrifuged at 1700 x g for 20 min at 4°C. After aspiration of supernatant s (except 
for total count tubes), radioactivity was counted in the pellets using a gamma-counter. The 
content of opioid peptides was calculated by comparison to the respective standard curves.  
To confirm the specificity of opioid peptide Abs, each Ab was tested with RIA using: 
A) samples containing either MENK (12.8 ng/ml), LENK, DYN or END (1.28 ng/ml) to 
examine whether the Abs specifically detect their respective opioid peptides; B) samples 
containing a combination of bestatin (5 µM – 5 mM) and thiorphan (1 µM – 10 mM) or P8B (1 
µM – 10 mM) to test whether opioid peptide Abs recognize peptidase inhibitors; C) samples 
containing metabolites of opioid peptides (i.e. H-Gly-Gly-Phe-Leu-OH, H-Gly-Gly-Phe-Met-
OH and H-Tyr-Gly-Gly-OH; 10 ng/ml for MENK or 1 ng/ml for LENK, DYN and END) to 
assess whether opioid peptide Abs recognize metabolites of opioid peptides. 
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2.3.10. Assessment of nociceptive thresholds in vivo  
 
These experiments were performed by my collaborator Dr. D. Labuz. Four days 
after CFA inoculation mechanical nociceptive thresholds were assessed using the paw 
pressure algesiometer (modified Randall-Selitto test), as described earlier (Stein et al., 
1990a; Machelska et al., 2003; Labuz et al., 2006). Rats (n = 2 – 3 per group) were gently 
restrained under paper wadding, and incremental pressure was applied via a wedge-shaped, 
blunt piston onto the dorsal surface of the hind paw. The paw pressure threshold (PPT) 
(cutoff at 250 g) required to elicit paw withdrawal was determined by averaging three 
consecutive trials separated by 15 s intervals. The sequence of paws was alternated between 
animals to avoid "order" effects. A combination of bestatin (5 mg) and thiorphan (0.8 mg) or 
P8B (1 mg) were injected i.pl. into inflamed paws together with a control IgG (2 µg; control 
group) or with Abs against MENK (2 µg), LENK (0.5 µg), END (1 µg) or DYN (0.5 µg). The 
doses of all substances were determined in pilot experiments. The substances were 
dissolved in 0.9% NaCl and injected in a total volume of 100 µl under brief isoflurane 
anesthesia. PPTs were measured before (baseline) and 5 min after injections.  
 
 
2.3.11. Statistical analysis 
 
Sigma Stat Version 3.5 for Windows software was used for statistical analyses. 
Multiple comparisons for independent data were analyzed by one-way analysis of variance 
(ANOVA) for normally distributed data or by one-way ANOVA on ranks for not normally 
distributed data. Two-way repeated-measures (RM) ANOVA was used for multiple 
comparisons of two treatments over time. Post-hoc multiple comparisons were performed 
using Bonferroni t test or Student-Newman-Keuls test. Linear regression analysis was used 
to evaluate dose-dependency. Data are presented as means ± standard error of the mean 
(SEM). Differences were considered significant if P < 0.05. 
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3. Results 
 
3.1. Quantitative characterization of leukocytes expressing APN and NEP in 
inflamed paws  
 
Single cell suspensions were prepared from rat hind paws inoculated with CFA 4 
days earlier, and processed for flow cytometry. To exclude nonhematopoietic cells and 
debris, cell suspensions were stained with an Ab against CD45, a hematopoietic cell marker, 
and gated on CD45+ cells (Fig. 3.1 A). Macrophages (CD45+CD163+) dominated at this stage 
of inflammation constituting 31.3% of CD45+ cells (Fig. 3.1 B and Fig. 3.2 B) followed by 
granulocytes (CD45+RP-1+) representing 16.6% (Fig. 3.1 D and Fig. 3.2 C) and by T-
lymphocytes (CD45+CD3+) comprising 4.1% of CD45+ cells (Fig. 3.1 F and Fig. 3.2 D). T-
lymphocytes were significantly less abundant than granulocytes and macrophages (P < 0.05, 
one-way ANOVA, Bonferroni t test; Fig. 3.2).  
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Figure 3.1. (previous page) Characterization of immune cell subpopulations in inflamed rat paws (A) 
Gating on hematopoietic cells (CD45 Ab). (B) Gating on macrophages (CD163 Ab). (C) Staining by 
control IgG2 Ab for anti-CD163. (D) Gating on granulocytes (RP-1 Ab). (E) Staining by control IgG1 Ab 
for anti-RP-1. (F) Gating on T cells (CD3 Ab). (G) Staining by control IgG3 Ab for anti-CD3. Cy5, PE 
and FITC represent fluorescent dyes conjugated with respective Abs. 
 
 
To evaluate CD45+ cell subpopulations expressing APN (CD13+) or NEP (CD10+) 
triple-color flow cytometry was employed. Of all CD45+ cells 22.6% were APN-positive 
(CD45+CD13+) and 12% were NEP-positive (CD45+CD10+) (Fig. 3.2 A). The analysis showed 
that 24.2% of macrophages expressed APN (CD45+CD163+CD13+) and 37.4% expressed 
NEP (CD45+CD163+CD10+) (Fig. 3.2 B). Among granulocytes 15.2% expressed APN 
(CD45+RP-1+CD13+) and 14.3% expressed NEP (CD45+RP-1+CD10+) (Fig. 3.2 C). APN and 
NEP were not detected in T-lymphocytes (Fig. 3.2 D). Minimal staining (0 - 3.4%) by 
respective isotype-matched control Abs confirmed staining specificity of Abs against APN, 
NEP (not shown) and each leukocyte subpopulation (Fig. 3.1 C, E and G).  
 
 
Figure 3.2. Quantification of leukocyte subpopulations expressing APN or NEP in inflamed rat paws. 
The cell nnumbers were calculated in relation to a fixed number of TruCOUNT® beads added to the 
cell suspensions. (A) Hematopoietic (CD45+) cells and CD45+ cells expressing APN (CD45+CD13+) or 
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NEP (CD45+CD10+). (B) Macrophages (CD163+) and macrophages expressing APN (CD163+CD13+) 
or NEP (CD163+CD10+). (C) Granulocytes (RP-1+) and granulocytes expressing APN (RP-1+CD13+) 
or NEP (RP-1+CD10+). (D) T-lymphocytes (CD3+). *P < 0.05, compared with CD163+; †P < 0.05, 
compared with RP-1+ and CD163+ (one-way ANOVA, Student-Newman-Keuls test). Nd, not detected. 
Data are expressed as means ± SEM. N = 7 rats per group. 
 
 
3.2. Role of APN and NEP in the degradation of opioid peptides released by 
immune cells 
 
3.2.1. Effects of APN and NEP inhibitors on the degradation of peptidase-
specific substrates  
 
To determine the enzymatic activity of APN the degradation of its specific synthetic 
substrate Ala-βNA to βNA was measured photospectrometrically. No βNA was detectable at 
the zero time points in all experiments (Fig. 3.3). Incubation of vital immune cells with Ala-
βNA for 4 h resulted in an accumulation of its metabolite βNA in inhibitor-free control groups 
(P < 0.001, two-way RM ANOVA, Bonferroni t test; Fig. 3.3 A and B). When cells were 
treated with either bestatin (5 – 20 mM) or P8B (0.1 – 10 mM) the βNA levels in supernatants 
dose-dependently decreased (P < 0.001, Linear regression, Fig. 3.3 A and B). βNA 
production was abolished by 20 mM of bestatin (Fig. 3.3. A) and was diminished by about 
69% by 10 mM of P8B (Fig. 3.3 B).  
To determine the enzymatic activity of NEP the degradation of its specific substrate 
Suc-Ala-Ala-Phe-pNA to pNA was examined. Incubation of immune cells with Suc-Ala-Ala-
Phe-pNA for 4 h resulted in a significant increase of pNA in inhibitor-free control groups (P < 
0.001, two-way RM ANOVA, Bonferroni t test; Fig. 3.3 C and D). pNA production was dose-
dependently blocked by thiorphan (8 – 10 mM) and diminished by up to 64% by P8B (0.1 – 
20 mM) (P < 0.001, Linear regression; Fig. 3.3 C and D).  
The actions of selective inhibitors were enzyme-specific because there were no 
significant effects of thiorphan (10 mM) on βNA production (i.e. APN activity) or of bestatin 
(10 mM) on pNA production (i.e. NEP activity) (P > 0.05, two-way RM; data not shown). 
Analysis of thiorphan (1 µM – 10 mM) and bestatin (5 µM – 20 mM) or P8B (1 µM – 20 mM) 
without APN and NEP substrates showed no signals, suggesting that inhibitors did not 
interfere with photospectrometric measurements.  
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Figure 3.3. Effects of APN and NEP inhibitors on the degradation of peptidase-specific substrates in 
vital immune cells. (A, B) Incubation with Ala-βNA (200 µM) alone for 4 h resulted in accumulation of 
the APN metabolite βNA in the supernatant. Substrate hydrolysis was dose-dependently blocked by 
bestatin (b) and diminished by P8B (P < 0.001, Linear regression). (C, D) Incubation with Suc-Ala-Ala-
Phe-pNA (100 µM) alone resulted in accumulation of the NEP metabolite pNA after 4 h. Substrate 
hydrolysis was dose-dependently prevented by thiorphan (t) and attenuated by P8B (P < 0.001, Linear 
regression). The metabolites were below the detection limit at 0h in all groups. §P < 0.001 (two-way 
RM ANOVA, Bonferroni t test). Nd, not detected. Data are expressed as means ± SEM. N = 3-8 
experiments per group. 
 
 
3.2.2. pH dependency of APN and NEP activity  
 
It has been previously reported that inflammation is accompanied by acidification of 
the affected tissues (Punnia-Moorthy, 1988). Measurements (in co-operation with Mrs. 
Spahn) by i.pl. insertion of a pH electrode revealed significantly lower pH values in inflamed 
(7.02 ± 0.05) as compared with non-inflamed rat paws (7.43 ± 0.02) (P < 0.001, t test, n = 4-
8).  
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To investigate whether the activities of APN and NEP were influenced by extracellular 
pH levels, immune cells isolated from inflamed paws were incubated for 4 h in RPMI-buffer 
under different pH conditions. As demonstrated in Fig. 3.4., changing pH values from 5.0 – 
8.0 did not significantly influence the levels of βNA (indicating APN activity) and pNA 
(indicating NEP activity) (P > 0.05, one-way RM ANOVA). 
 
 
Figure 3.4. Effects of pH on the activity of APN and NEP in vital immune cells. (A) Incubation of cells 
with the APN substrate Ala-βNA (200 µM) at different pH values (5.0 - 8.0) did not influence 
accumulation of its metabolite βNA over 4 h. (B) Incubation of cells with the NEP substrate Suc-Ala-
Ala-Phe-pNA (100 µM) at different pH values (5.0 - 8.0) did not influence accumulation of its 
metabolite pNA over 4 h (P > 0.05, one-way RM ANOVA). Data are expressed as means ± SEM. N = 
3-5 experiments per group. 
 
 
3.2.3. Effects of selective APN and NEP inhibitors on opioid peptides released 
from immune cells  
 
The next step was to ascertain the release of endogenous opioid peptides from vital 
inflammatory cells. The extracellular levels of immunoreactive MENK and LENK increased 
1.3 and 2.3 fold, respectively, over the first 4 h (P < 0.01) while those of DYN and END 
increased 2.4 and 2.1 fold, respectively, at 8 h (P < 0.05) (two-way RM ANOVA, Bonferroni t 
test; Fig. 3.5). To exclude that these increases in immunoreactivities were due to cross-
reactivity of Abs with opioid peptide metabolites, the standard analogs Tyr-Gly-Gly-OH, Gly-
Gly-Phe-Met-OH and Gly-Gly-Phe-Leu-OH were tested in RIA for each of the four opioid 
peptides. No immunoreactivities were detected (data not shown). As shown in Fig. 3.5 A and 
B, control MENK and LENK began to decrease at 6 h and dropped to baseline levels at 8 h 
(P < 0.001 and P < 0.01, respectively, two-way RM ANOVA, Bonferroni t test). 
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A combination of bestatin (5 mM) and thiorphan (1 mM) increased MENK 
concentrations at 4 - 8 h of incubation when compared to baseline (0 h) of the inhibitor-
treated group (P < 0.01, two-way RM ANOVA, Bonferroni t test; Fig. 3.5 A). When compared 
with control groups the inhibitors decreased MENK levels at 0 h and 4 h (P < 0.05). Also, 
inhibitor treatment did not increase MENK over level of control group at 6 - 8 h (P > 0.05) 
(two-way RM ANOVA, Bonferroni t test; Fig. 3.5 A). No changes of LENK levels were 
detected at 0 h to 6 h between groups and treatment with bestatin and thiorphan significantly 
elevated (by 47 %) LENK levels compared with control at 8 h (P < 0.001, two-way RM 
ANOVA, Bonferroni t test; Fig. 3.5 B). Levels of DYN and END significantly increased over 
time in control and inhibitor-treated groups (P < 0.05), but were not significantly influenced by 
inhibitors (P > 0.05) (two-way RM ANOVA, Bonferroni t test; Fig. 3.5 C and D). 
Concentrations of inhibitors in these experiments were lower than in experiments depicted in 
Fig. 3.3 A and C, because a combination of bestatin and thiorphan in doses higher than 5 
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Figure 3.5. (previous page) Effects of the combination of bestatin (b) and thiorphan (t) on the levels of 
opioid peptides released from immune cells over 8 h of incubation. Amounts of MENK (A), LENK (B), 
DYN (C) and END (D) were determined in the supernatants of immune cells immediately after addition 
(0 h) of buffer (white bars) or of bestatin and thiorphan (black bars) and at 4 - 8 h later. *P < 0.05; #P < 
0.01; §P < 0.001 (two-way RM ANOVA, Bonferroni t test). Data are expressed as means ± SEM. N = 
3-4 experiments per group.  
 
 
3.2.4. Effects of a dual APN and NEP inhibitor on opioid peptide levels released 
from immune cells  
 
We examined the effects of P8B on the levels of opioid peptides secreted from 
immune cells during 8 h of incubation. Similar to the above experiments (Fig. 3.5), 
extracellular levels of MENK and LENK in control groups increased over the first 4 h (P < 
0.001) but began to decrease at 6 h and significantly dropped at 8 h (P < 0.05 for MENK and 
P < 0.001 for LENK) (two-way RM ANOVA, Bonferroni t test; Fig. 3.6 A and B). P8B (5 mM) 
increased levels of MENK at 4 - 8 h and of LENK at 8 h when compared to baseline (0 h) of 
the respective inhibitor-treated groups (P < 0.05, two-way RM ANOVA, Bonferroni t test; Fig. 
3.6 A and B). The inhibitor significantly decreased LENK levels compared with control groups 
at all time points of incubation (P < 0.001) and it did not increase both peptides compared 
with the respective control groups at 8 h (P > 0.05, two-way RM ANOVA, Bonferroni t test; 
Fig. 3.6 A and B). Levels of DYN and END significantly increased over time in control groups 
(P < 0.05) and were not significantly changed by P8B (P > 0.05) (two-way RM ANOVA, 
Bonferroni t test; Fig. 3.6 C and D). Concentrations of inhibitors in these experiments were 
chosen similar to bestatin in experiments above. 
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Figure 3.6. Effects of P8B on the levels of opioid peptides released from immune cells during 8 h of 
incubation. Amounts of MENK (A), LENK (B), DYN (C) and END (D) were determined in the 
supernatants of immune cells immediately after addition (0 h) of buffer (white bars) or of P8B (gray 
bars) and after 4, 6 and 8 h. *P < 0.05; §P < 0.001 (two-way RM ANOVA, Bonferroni t test). Data are 
expressed as means ± SEM. N = 3-4 experiments per group. 
 
 
3.3. APN and NEP activity on immune cell membranes 
 
3.3.1. Effects of APN and NEP inhibitors on the degradation of peptidase-
specific substrates 
 
The next step was to study peptidase activities in immune cell membrane 
preparations from leukocytes infiltrating inflamed paws. APN and NEP enzymatic activities 
were assessed by photospectrometrically measuring the metabolites of their specific 
substrates (as described in paragraph 3.2.1.) and no substrate hydrolysis was detected at    
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0 h in any experiment (Fig. 3.7). Incubation of immune cell membrane suspensions with the 
APN substrate Ala-βNA for 4 h resulted in an accumulation of its metabolite βNA in inhibitor-
free control experiments (P < 0.001, two-way RM ANOVA, Bonferroni t test; Fig. 3.7 A and 
B). Co-incubation with bestatin (50 µM) or P8B (1 – 10 µM) fully abolished the generation of 
βNA (P < 0.001, two-way RM ANOVA, Bonferroni t test; Fig. 3.7 A and B).  
Incubation of immune cell membrane suspensions with the NEP substrate Suc-Ala-
Ala-Phe-pNA for 4 h led to enhanced levels of pNA in inhibitor-free control groups (P < 0.001, 
two-way RM ANOVA, Bonferroni t test; Fig. 3.7 C and D). This pNA production was fully 
blocked by thiorphan (1 – 10 µM) and P8B (1 – 10 µM) (P < 0.001, two-way RM ANOVA, 
Bonferroni t test; Fig. 3.7 C and D).  
 
 
Figure 3.7. Effects of APN and NEP inhibitors on the degradation of peptidase-specific substrates in 
immune cell membranes. (A, B) APN activity was determined by the degradation of Ala-βNA (200 µM) 
to its metabolite βNA after 4 h of incubation in the inhibitor-free control groups. βNA production was 
prevented by bestatin (b) or P8B. (C, D) NEP activity was determined by degradation of Suc-Ala-Ala-
Phe-pNA (100 µM) to its metabolite pNA after 4 h of incubation in inhibitor-free control groups. pNA 
production was prevented by thiorphan (t) or P8B. The metabolites were below the detection limit at 
time 0 h in all groups. §P < 0.001 (two-way RM ANOVA, Bonferroni t test). Nd, not detected. Data are 
expressed as means ± SEM. N = 3-4 experiments per group.  
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3.3.2. Effects of selective APN and NEP inhibitors on the degradation of 
exogenous opioid peptides 
 
To assess the effects of selective APN and NEP inhibitors on the degradation of 
exogenous opioid peptides, immune cell membrane suspensions were incubated with MENK 
(12.8 ng/ml), LENK, DYN or END (1.28 ng/ml) in the absence or presence of combinations of 
bestatin (5 – 500 µM) and thiorphan (1 – 100 µM), and 4 h later opioid levels were measured 
with RIA. There were no statistically significant differences in basal opioid peptide levels at   
0 h of incubation between inhibitor-free controls and groups containing a combination of 
bestatin and thiorphan (P > 0.05, two-way RM ANOVA; Fig. 3.8). Significantly decreased 
amounts of MENK (by 70%; P < 0.001), LENK (by 77%; P < 0.01), DYN (by 46%; P < 0.05) 
and END (by 39%; P < 0.05) (two-way RM ANOVA, Bonferroni t test; Fig. 3.8) were observed 
after 4 h of incubation without inhibitors (controls). Combinations of bestatin (5 - 500 µM) and 
thiorphan (1 - 100 µM) dose-dependently prevented the degradation of MENK and LENK (P 
< 0.01 and P < 0.001, respectively, Linear regression; Fig. 3.8 A and B). Bestatin and 
thiorphan did not significantly change the levels of DYN and END (P > 0.05, two-way RM 
ANOVA, Bonferroni t test; Fig. 3.8 C and D).  
To examine cross-reactivity of Abs, the standard MENK, LENK, DYN and END 
peptides were tested in the respective three complementary RIAs. MENK produced a 
minimal signal when tested in the LENK RIA, and therefore all subsequent LENK data were 
corrected by subtracting this signal. There was no cross-reactivity in any other combinations 
(data not shown). To determine whether opioid peptide Abs recognize peptidase inhibitors, 
the inhibitors were also tested in all four RIAs. Bestatin (50 µM – 5 mM) in a combination with 
thiorphan (10 µM – 1 mM) produced a small signal when tested with the LENK RIA, and 
therefore all LENK data (with inhibitors) were corrected by subtracting this signal. To assess 
whether peptidase inhibitors cross-react with the standard opioid peptides, MENK, serving as 
an example of all opioid peptides, was combined with bestatin (5 µM - 5 mM) and thiorphan 
(1 µM - 1 mM) in standard curves and tested with RIA. There were no differences between 
standard curves with and without peptidase inhibitors (data not shown).  
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Figure 3.8. Effects of the combination of bestatin (b) and thiorphan (t) on the degradation of 
exogenous opioid peptides in immune cell membranes. Membrane suspensions were incubated with 
MENK (A), LENK (B), DYN (C) or END (D), and with control buffer or combinations of thiorphan and 
bestatin. Measurements were performed immediately after addition of buffer or inhibitors (white bars) 
and 4 h later (black bars). Inhibitors dose-dependently increased MENK and LENK concentrations (P 
< 0.01 and P < 0.001, respectively, Linear regression). Levels of DYN and END were not significantly 
changed by the inhibitors (P > 0.05, two-way RM ANOVA, Bonferroni t test). *P < 0.05; #P < 0.01; §P < 
0.001 (two-way RM ANOVA, Bonferroni t test). Data are expressed as means ± SEM. N = 3-5 
experiments per group.  
 
 
3.3.3. Effects of a dual APN and NEP inhibitor on the degradation of exogenous 
opioid peptides  
 
To investigate the effect of P8B, immune cell membrane suspensions were incubated 
with standard MENK (12.8 ng/ml), LENK, DYN or END (1.28 ng/ml) in the absence or 
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presence of P8B (1 – 100 µM), and opioid levels were measured with RIA 4 h later. There 
were no significant differences in basal opioid peptide levels immediately after addition of 
buffer or P8B (0 h) (P > 0.05, two-way RM ANOVA, Bonferroni t test; Fig 3.9). Significantly 
decreased amounts of MENK (by 37%), LENK (by 77%), DYN (by 47%) and END (by 37%) 
(P < 0.001, two-way RM ANOVA, Bonferroni t test; Fig. 3.9) were observed after 4 h. 
Treatments with P8B (1 - 100 µM) dose-dependently increased MENK and LENK (P < 0.05, 
Linear regression; Fig. 3.9 A and B) but did not significantly change the levels of DYN and 
END (P > 0.05, two-way RM ANOVA, Bonferroni t test; Fig. 3.9 C and D). 
To examine whether P8B cross-reacts with opioid peptides, standard LENK, serving 
as example of all opioid peptides, was combined with P8B (5 mM) in RIA. There were no 
differences between the standard curves with and without P8B (data not shown). 
 
 
Figure 3.9. Effects of P8B on the degradation of exogenous opioid peptides in immune cell 
membranes. Membrane suspensions were incubated with MENK (A), LENK (B), DYN (C) or END (D) 
and with buffer (control) or P8B. Measurements were performed immediately after addition of buffer or 
inhibitor (white bars) and 4 h later (gray bars). The inhibitor dose-dependently prevented the 
degradation of MENK and LENK (P < 0.05, Linear regression) but not of END and DYN (P > 0.05,two-
way RM ANOVA, Bonferroni t test). *P < 0.05; §P < 0.001 (two-way RM ANOVA, Bonferroni t test). 
Data are expressed as means ± SEM. N = 3-5 experiments per group. 
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3.4. Activity of APN and NEP expressed on peripheral nerves 
 
3.4.1. Effects of APN and NEP inhibitors on the degradation of peptidase-
specific substrates in nerve preparations 
 
Similar to experiments with vital immune cells and immune cell membranes (see 
paragraphs 3.2.1 and 3.3.1), APN and NEP activities in suspensions of sciatic nerve terminal 
branches were determined photospectrometrically using peptidase specific substrates. No 
metabolites were detectable at the beginning (0 h) of incubations in any experiment (Fig. 
3.10 and 3.11). Incubation of nerve suspensions with the APN substrate Ala-βNA for 4 h 
resulted in an accumulation of its metabolite βNA in inhibitor-free control groups (P < 0.001, 
two-way RM ANOVA, Bonferroni t test; Fig. 3.10 A and Fig. 3.11 A and B). There was no 
significant difference between inflamed and non-inflamed sides (P > 0.05, two-way RM 
ANOVA; Fig. 3.10 A). Both bestatin (5 – 15 mM) and P8B (1 – 10 mM) dose-dependently 
diminished the generation of βNA in nerve suspensions from inflamed paws (P < 0.001, 
Linear regression; Fig. 3.11 A and B). βNA production was fully blocked by 15 mM of bestatin 
and diminished by about 61% by 10 mM of P8B.  
Incubation of nerve suspensions with the NEP specific substrate Suc-Ala-Ala-Phe-
pNA for 4 h resulted in a significant accumulation of its metabolite pNA in inhibitor-free 
control groups (P < 0.001, two-way RM ANOVA, Bonferroni t test; Fig. 3.10 B and Fig. 3.11 C 
and D). A significantly higher (by 42%) amount of pNA accumulated over 4 h in nerve 
suspensions from inflamed compared to non-inflamed limbs (P < 0.001, two-way RM 
ANOVA, Bonferroni t test; Fig. 3.10 B). The pNA production was dose-dependently blocked 
in the presence of either thiorphan (1 – 8 mM) or P8B (1 – 10 mM) in nerve suspensions 
from inflamed paws (P < 0.001, Linear regression; Fig. 3.11 C and D). NEP activity was fully 
blocked by 8 mM of thiorphan and was decreased by 92% by 10 mM of P8B. 
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Figure 3.10. Activity of APN and NEP in suspensions of sciatic nerve terminal branches innervating 
inflamed and non-inflamed paws. (A) APN activity was determined by the degradation of Ala-ß-NA 
(200 µM) to its metabolite βNA after 4 h of incubation in peripheral nerves. There was no significant 
difference between inflamed and non-inflamed sides (P > 0.05, two-way RM ANOVA, Bonferroni t 
test). (B) NEP activity was determined by the degradation of Suc-Ala-Ala-Phe-pNA (100 µM) to its 
metabolite pNA after 4 h incubation in peripheral nerves. pNA production was increased in nerve 
suspensions from inflamed limbs. The metabolites were below detection limit at 0 time points in all 
groups. §P < 0.001; ns, not significant (two-way RM ANOVA, Bonferroni t test). Nd, not detected. Data 
are expressed as means ± SEM. N = 3-8 experiments per group.  
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Figure 3.11. (previous page) Effects of APN and NEP inhibitors on the degradation of peptidase-
specific substrates in suspensions of sciatic nerve terminal branches innervating inflamed paws. (A, 
B) Incubation with Ala-βNA (200 µM) alone for 4 h resulted in accumulation of the APN metabolite 
βNA in the supernatant. Prevention of substrate hydrolysis was assessed in the presence of bestatin 
(b) and diminished by P8B (P < 0.001, Linear regression). (C, D) Incubation with Suc-Ala-Ala-Phe-
pNA (100 µM) alone resulted in accumulation of the NEP metabolite pNA after 4 h. Prevention of 
substrate hydrolysis was examined in the presence of thiorphan (t) or P8B (P < 0.001, Linear 
regression). The metabolites were below detection limit at 0 time points in all groups. §P < 0.001 (two-
way RM ANOVA, Bonferroni t test). Nd, not detected. Data are expressed as means ± SEM. N = 3-8 
experiments per group.  
 
 
3.4.2. Effects of selective APN and NEP inhibitors on the degradation of 
exogenous opioid peptides in nerve preparations 
 
Next we assessed the functional relevance of APN and NEP in peripheral nerves for 
the degradation of exogenously added opioid peptides. No significant differences in the basal 
opioid peptide levels were measured at 0 time points among groups (P > 0.05, two-way RM 
ANOVA, Bonferroni t test; Fig 3.12). Four h incubation of the suspensions of sciatic nerve 
terminal branches with standard MENK (12.8 ng/ml), LENK, DYN or END (1.28 ng/ml) 
showed 78% decrease of MENK and 79% decrease of LENK compared to 0 h (P < 0.01, 
two-way RM ANOVA, Bonferroni t test; Fig. 3.12 A and B). Levels of DYN were lowered by 
57% and of END by 83% (P < 0.05, two-way RM ANOVA, Bonferroni t test; Fig. 3.12 C and 
D). In the samples treated with a combination of bestatin (0.5 - 10 mM) and thiorphan (0.1 - 5 
mM) for 4 h, the degradation of MENK and LENK was dose-dependently prevented (P < 
0.001, Linear regression; Fig. 3.12 A and B). The DYN degradation was also dose-
dependently prevented (P < 0.001, Linear regression; Fig. 3.12 C) and its amounts increased 
significantly over the basal (0 h) levels after treatment with high concentrations of bestatin 
and thiorphan (P < 0.001, two-way RM ANOVA, Bonferroni t test; Fig. 3.12 C). Bestatin and 
thiorphan did not significantly change the levels of END (P > 0.05, two-way RM ANOVA, 
Bonferroni t test; Fig. 3.12 D).  
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Figure 3.12. Effects of the combination of bestatin (b) and thiorphan (t) on the degradation of 
exogenous opioid peptides in peripheral nerve suspensions. Sciatic nerve terminal branches 
suspensions were incubated with exogenous MENK (A) LENK (B) DYN (C) or END (D) and with a 
buffer (control) or with bestatin and thiorphan. Measurements were performed immediately after 
addition of buffer or inhibitors (white bars) and 4 h later (black bars). Inhibitors dose-dependently 
prevented the degradation of MENK, LENK and DYN (P < 0.001, Linear regression) but not of END (P 
> 0.05, two-way RM ANOVA, Bonferroni t test). *P < 0.05; #P < 0.01; §P < 0.001 (two-way RM 
ANOVA, Bonferroni t test). Data are expressed as means ± SEM. N = 3-5 experiments per group.  
 
 
3.4.3. Effects of a dual APN and NEP inhibitor on the degradation of exogenous
 opioid peptides in nerve preparations 
 
Four h incubation of the suspensions of sciatic nerve terminal branches with standard 
MENK (12.8 ng/ml), LENK, DYN or END (1.28 ng/ml) resulted in significant degradation of 
MENK (by 79%; P < 0.001), LENK (by 88%; P < 0.001), DYN (by 46%; P < 0.01) and of 
END(by 74%; P < 0.001) compared to 0 h in inhibitor-free control groups (two-way ANOVA,  
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Bonferroni t test; Fig. 3.13). No significant differences in basal opioid peptide levels 
measured at 0 time points among groups (P > 0.05, two-way RM ANOVA, Bonferroni t test; 
Fig. 3.13). Treatment with P8B (0.1 - 10 mM) dose-dependently prevented the degradation of 
MENK and LENK (P < 0.001, Linear regression), until enkephalin levels were not significantly 
different compared with the basal (0 h) control (P > 0.05, two-way RM ANOVA, Bonferroni t 
test; Fig. 3.13 A and B). Also, DYN levels were dose-dependently elevated by P8B  (P < 
0.001, Linear regression; Fig. 3.13 C), and its amounts increased significantly over the basal 
(0 h) levels after treatment with the highest concentration of P8B (P < 0.001, two-way RM 
ANOVA, Bonferroni t test; Fig. 3.13 C). The levels of END were not significantly altered by 
P8B (P > 0.05, two-way RM ANOVA, Bonferroni t test; Fig. 3.13 D).  
 
 
Figure 3.13. Effects of P8B on the degradation of exogenous opioid peptides in peripheral nerve 
suspensions incubated with exogenous MENK (A), LENK (B), DYN (C) or END (D) and with a buffer 
(control) or P8B. Measurements were performed immediately after addition of buffer or inhibitor (white 
bars) and 4 h later (gray bars). The inhibitor dose-dependently prevented the degradation of MENK 
and LENK (P < 0.001, Linear regression). P8B (10 mM) significantly increased levels of DYN (P < 
0.001, two-way RM ANOVA, Bonferroni t test). Levels of END were not significantly changed by P8B 
(P > 0.05, two-way RM ANOVA, Bonferroni t test). #P < 0.01; §P < 0.001 (two-way RM ANOVA, 
Bonferroni t test). Data are expressed as means ± SEM. N = 3-5 experiments per group.  
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3.5. In vivo effects of APN and NEP inhibitors on peripheral opioid 
antinociception 
 
Four days after i.pl. injection of CFA rats developed hyperalgesia characterized by 
significantly decreased paw pressure thresholds (PPT) in inflamed paws (37.7 ± 1.04 g) 
compared with contralateral non-inflamed paws (69.2 ± 1.3 g). Intraplantarly injection of a 
combination of bestatin (5 mg) and thiorphan (0.8 mg) or of P8B (1 mg) into inflamed paws 
produced antinociception represented by increased PPT in inflamed paws as compared to 
baseline (Fig. 3.14 A and B). Antinociceptive effects of the inhibitors were fully reversed by 
i.pl. co-injected Abs against MENK (2 µg), LENK (0.5 µg) or DYN (0.5 µg) but not by anti-
END (1 µg) (Fig. 3.14 A and B). No changes were observed in contralateral non-inflamed 




Figure 3.14. Antinociceptive effects produced by APN and NEP inhibitors injected into inflamed hind 
paws (white bars). (A) Reversibility of i.pl. bestatin (5 mg) and thiorphan (0.8 mg)-induced 
antinociception by co-injected anti-MENK (2 µg) or anti-DYN (1 µg). (B) Reversibility of P8B (0.1 mg)-
induced antinociception by co-injected anti-MENK (2 µg), anti-LENK (0.5 µg) or anti-DYN (1 µg). 
Injection of anti-END (1 µg) only slightly decreased inhibitor-induced antinociception. Dashed lines 
represent baseline PPT measured 4 days after induction of inflammation but before drug injections. 
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4. Discussion 
 
The major findings of this study are: 
a) APN and NEP are expressed in granulocytes and macrophages, but not in T 
lymphocytes, infiltrating painful inflamed tissue.  
b) Leukocytic and neuronal APN and NEP degraded their specific synthetic substrates, 
which could be dose-dependently prevented with selective inhibitors of APN (bestatin) 
and NEP (thiorphan) as well as with a novel dual inhibitor P8B. This was 
demonstrated in vital immune cells as well as in immune cell membranes and 
peripheral nerves. Furthermore, the enzymatic activity of neuronal NEP, but not of 
APN, was higher in nerves innervating inflamed compared to non-inflamed tissue. 
c) Immune cell-released MENK and LENK, but not DYN and END, underwent 
degradation. Catabolism of extracellular LENK was prevented with selective APN and 
NEP inhibitors. This was not in the case of MENK and LENK after treatment with 
P8B, probably because inhibitors paradoxically diminished enkephalin levels 
compared to inhibitor-free groups.  
d) In immune cell membranes and peripheral nerves, exogenously added MENK and 
LENK appeared as preferential targets for leukocytic and neuronal APN and NEP. 
This was demonstrated by prevention of enkephalin degradation with specific and 
dual peptidase inhibitors.  In addition, DYN degradation was dependent on neuronal 
APN and NEP.  
e) Both specific and dual APN and NEP inhibitors injected into inflamed rat hind paws 
produced antinociception which was fully reversed by a co-injection with Abs against 
MENK, LENK or DYN, but only partially by Ab against END. 
 
 
4.1. Expression of APN and NEP in leukocytes  
 
Our group has provided evidence that opioid peptides released from immune cells 
accumulating in inflamed tissues decrease inflammatory pain in animals and humans 
(reviewed in Busch-Dienstfertig and Stein, 2009). The focus of the present studies was to 
investigate the degradation of opioid peptides by APN and NEP in painful inflamed tissue 
following CFA application. As a source of peptidases we analyzed immune cells as they 
densely infiltrate such tissue at this advanced stage of inflammation (4 days following CFA). 
Indeed, we found numerous hematopoietic CD45+ cells, among which we identified 
macrophages (31.3%), granulocytes (16.6%) and T lymphocytes (4.1%), confirming our  
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earlier studies where accumulation of macrophages together with the precursor monocytes 
(~55%), granulocytes (10 - 35%) and 5% lymphocytes in inflamed tissue was shown (Stein et 
al., 1990; Przewlocki et al., 1992; Rittner et al., 2001; Brack et al., 2004a,b). Furthermore, we 
extended these findings by examining the expression of APN and NEP in CD45+ cell 
subpopulations with triple-color flow cytometry. This analysis revealed that APN was 
expressed by 15.2% granulocytes and 24.2% macrophages, while NEP was expressed by 
14.3% granulocytes and 37.4% macrophages. T lymphocytes did not express any of the two 
peptidases. Previously, very few studies examined leukocytic expression of APN and NEP 
and most of them were performed in healthy animals and humans. Thus, APN was shown to 
be present on bone marrow monocytes, macrophages, granulocytes, dendritic and B 
lymphocytes, but not on thymocytes or spleen T cells in mice and only on pre-mature T 
lymphocytes or on thymic stromal cells in adult rats (Hansen et al., 1993; Jardinaud et al., 
2004). Another study showed that T lymphocytes become APN-negative upon maturation, 
which resulted in its absence in the spleen or peripheral blood lymphocytes in humans 
(Riemann et al., 1999). NEP is expressed on early normal T- and B-cell progenitors (Shipp 
and Look, 1993; Mari et al., 1994). Also, NEP was shown on different T cell populations of 
healthy rat thymocytes (Amantini et al., 2008). Other studies that used FACS, determined 
NEP on granulocytes in mice spleen cells (Braun et al., 1983) and peripheral blood of 
patients with open heart surgery (Schroeter et al., 2007). Regarding pathological conditions, 
NEP was found in circulating and synovial fluid granulocytes, monocytes and in T 
lymphocytes of patients with juvenile chronic arthritis (Simonini et al., 2005). APN was 
detected with flow cytometry and Western blot in T lymphocytes in synovial fluid, but not in 
peripheral blood, of rheumatoid and juvenile chronic arthritis patients (Riemann et al., 1993). 
Other leukocyte subsets were not assessed in that study. In both studies APN and NEP 
expressing T lymphocytes were detected under pathological condition, but the state of 
inflammation is chronic, characterized by enhanced T cell infiltration. In the present study the 
absence of expression of both peptidases in T lymphocytes might be related to a relatively 
low percentage of these cells in our inflammatory model. Together, expanding those earlier 
observations our comprehensive analysis of both peptidases in all major leukocyte 
subpopulations infiltrating painful inflamed tissue demonstrated that granulocytes and 
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4.2. Functionality of leukocytic and neuronal APN and NEP assessed by the 
degradation of their specific substrates  
 
To decrease inflammatory pain opioid peptides secreted from immune cells act at 
opioid receptors on peripheral sensory nerves in injured tissues (reviewed in Busch-
Dienstfertig and Stein, 2009). The expression of opioid degrading enzymes APN and NEP on 
neuronal tissues was investigated previously. Thus, APN was shown in brain and in the 
spinal cord of healthy rats (Watt et al., 1989; Noble et al., 2001; Jardinaud et al., 2004). One 
study assessed APN expression in pig peripheral nerves using immunohistochemistry and 
detected it in microvessels and perineurium of femoral and splenic nerves (Barnes et al., 
1991). The expression of NEP was previously intensive investigated in the CNS as well as in 
kidney, lungs and salivary glands (Sales et al., 1991, Dutriez et al., 1992). In peripheral 
nerves, NEP was demonstrated in Schwann cell membranes of the sciatic, splenic and 
vagus nerves from pig (Matsas et al., 1986; Barnes et al., 1991). Further, in healthy rats and 
under pathological conditions, NEP was detected in non-myelin-forming cells of 
unmyelinated fibers and very weakly with Schwann cells of large diameter fibers (Kioussi et 
al., 1992, 1995). 
 
 
4.2.1. APN and NEP activity is not dependent on pH values 
 
The next step was to verify the activity of APN and NEP in the sciatic nerve and 
leukocytes from inflamed tissue. Substrate specificity of zinc metallopeptidases essentially 
ensure by Van der Waals and ionic interactions between their active subunits and the 
corresponding moieties of the substrate. Substrate specificity is also determined by several 
hydrogen bonds between groups of the bound molecule and the polar residues of the 
peptidases (Roques et al., 1993). Thus, the possibility insists that different ph values could 
influence the affinity between substrates and enzymes. Most studies testing activities of APN 
and NEP were done in tissues from healthy animals and humans under neutral pH 
conditions. It was not clear whether the inflammation in our CFA model changes the function 
of both peptidases. Although it is generally accepted that inflammation is associated with 
high tissue acidity the available data are inconsistent. The pH values measured in vivo and in 
vitro experiments ranges from acidic 5.8 to alkaline 8.3, as summarized by Punnia-Moorthy 
(1988). Studies in short-lasting (6 – 8 h) inflammation induced by carrageenan, dextran and 
staphylococcus aureus injected into rat skin showed a small lowering of pH (by about 0.5) in 
inflamed tissues (Punnia-Moorthy, 1987, 1988). To mimic the in vivo conditions in the in vitro 
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assays we assessed pH in inflamed rat paws and found a small decrease in pH from 7.4 in 
non-inflamed paws to 7.0 in inflamed paws. In an in vitro study using natural killer leukocytes, 
isolated from spleen of healthy rats, a decreased APN activity in the specific substrate 
degradation was observed at acidic pH values (Amoscato et al., 1994). Therefore, using 
immune cells isolated from inflamed paws we analyzed the activities of APN and NEP, 
measured by the degradation of their specific substrates, within a pH range of 5.0 – 8.0. We 
detected no significant differences between various pH values, suggesting no major 
influence of the acidity on APN and NEP function in our experiments. Based on these 
findings, we decided to perform all in vitro assays at pH level of 7.4 and a temperature of 
37°C, according to Florentin and colleagues (1984).   
 
 
4.2.2. Prevention of APN - induced specific substrate degradation with 
selective and dual inhibitors 
 
A common way to assess the enzyme activity is to evaluate the degradation of its 
specific substrate(s) and verify the specificity of such effect by testing selective enzyme 
inhibitors. We confirmed that APN was functional in tissues from painful inflamed rat paws as 
we recorded a significant degradation of APN specific substrate Ala-βNA to its metabolite 
βNA. In vital immune cells and their membranes the degradation rate was 17 and 29 µmol/h 
(34% - 58% of possible hydrolysis), respectively. This is a higher degradation rate of Ala-βNA 
than 2.1 µmol/h measured in peritoneal macrophages or 10.2 nmol/h in spleen T cells from 
healthy mice (Miller et al., 1994a, 1994b). However, our results are comparable to those by 
Balog and colleagues (1999) and Marotti and co-workers (2000), who recorded Ala-βNA 
hydrolysis with the rate of about 37% - 50% during 1 h in blood neutrophils of healthy 
humans. None of the previous studies examined APN activity in leukocytes infiltrating 
pathological tissues.  
So far, only one study assessed APN activity in peripheral nerves from young pigs, 
but the influence of inflammation was not addressed (Barnes at al., 1991). We now 
demonstrate that Ala-βNA was hydrolyzed in sciatic nerve terminal branches innervating both 
non-inflamed and inflamed rat hind paws. As the Ala-βNA degradation rates were similar in 
nerves from both hind paws (10 mmol/h), it appears that the inflammation does not affect the 
activity of APN. It seems that APN is more active in neuronal tissue, but the hydrolysis rate 
could not compare to immune cell assays because of the method (see paragraph 2.3.6.).  
Subsequently, we verified the specificity of APN action as the enzyme ability to 
metabolize its specific substrate was dose-dependently and fully blocked by its selective 
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inhibitor bestatin in vital immune cell (20 mM), their membranes (50 µM) as well as in sciatic 
nerves (15 mM). Such experiments using bestatin in preparations from CNS structures or 
peripheral nerves have not been performed previously. Nevertheless, the requirement for 
higher bestatin doses to block APN in intact immune cells versus their membranes was 
found in earlier studies. For example, bestatin (0.1 mM) decreased the generation of βNA by 
about 50% in intact human neutrophils, but by 88% in neutrophil membranes (Marotti et al., 
2000). Also, although such comparison has not been directly addressed by Amoscato and 
colleagues (1994), these authors used bestatin in a dose of 3 mM to obtain 60% inhibition of 
APN activity using Leu-pNA as a substrate, in rat intact natural killer cells. None of those 
previous studies examined bestatin in a dose-dependent fashion. Interestingly, bestatin has 
been shown to passively enter immune cells, bind and block the cytosolic aminopeptidases 
(Constam et al., 1995; Scornic and Botbol, 2001) that could explain the necessity for 
relatively high bestatin concentrations to block APN action in intact cells. 
Next we tested the effect of a new dual APN and NEP inhibitor P8B on APN action. In 
immune cell membranes, the APN activity was fully blocked by P8B in a concentration of 1 
µM. However, in vital immune cells and the sciatic nerves the generation of βNA could be 
dose-dependently but partially diminished by about 69% and 61% by 10 mM of P8B, 
respectively. P8B was not tested to enter immune cells, but the use of higher P8B doses in 
intact immune cells versus their membranes is in line with our experiments using bestatin 
(discussed above). P8B is a new compound and was only tested by our corroborators who 
synthesized this inhibitor (Chen et al., 1998, 2000). These authors used in vitro assay in 
which activity of APN purified from hog kidney was tested by its ability to degrade Ala-p-
nitroaniline as a specific substrate. In such conditions P8B displayed a dissociation constant 
Ki value of 4.8 nM, which implies that the complex of enzyme-inhibitor is stabile and therefore 
the affinity of the inhibitor to APN is high. The P8B selectivity toward APN was further 
confirmed by the finding that the activity of another peptidase aminopeptidase A was poorly 
inhibited by P8B displaying 1000 fold less affinity to that enzyme (Chen et al., 1998). The 
differences between the studies might be related to the use of a purified APN by Chen et al. 
(1998) versus nerves and vital immune cells as APN source, requiring higher P8B doses, in 
line with the experiments using bestatin, in our study. Together, we have clearly 
demonstrated the function of leukocytic and neuronal APN by means of its specific substrate 
degradation in a model of painful inflammation. 
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4.2.3. Prevention of NEP activity on specific substrate degradation with 
selective and dual inhibitors 
 
To assess NEP activity, the degradation of several synthetic substrates, such as 
chromogenic (Suc-Ala-Ala-Phe-pNA) and fluorogenic (dansyl-D-Ala-Gly-Phe(pNO2)-Gly, 
peptides, to their metabolites measured with photospectrometry or fluorospectrometry has 
been employed. The peptidase activity was tested in mouse and rat brain, spinal cord, ileum, 
lung as well as in human neutrophils and the corresponding membranes (Florentin et al., 
1984; Marotti et al., 2000; Balog et al., 2001). We validated NEP activity in inflamed paw 
tissues by showing the metabolism of its specific substrate Suc-Ala-Ala-Phe-pNA to pNA. 
Degradation rate reached 12.5 µmol/h in vital immune cells and 4 µmol/h in their 
membranes. This hydrolysis rate was higher than 0.23 µmol/h in neutrophils from healthy 
human volunteers (Balog et al., 2001), which suggested that NEP activity is increased in 
inflammation. There are no other studies examining immune cells from injured tissues. 
We also demonstrated that Suc-Ala-Ala-Phe-pNA was hydrolyzed at a rate of 3 
mmol/h in sciatic nerve terminal branches isolated from non-inflamed and at 5 mmol/h from 
inflamed rat hind paw. The NEP activity in peripheral nerves was recorded previously, but the 
degradation rate cannot directly compare with this studies which used another specific 
substrate. Kioussi and colleagues (1992) could observe NEP activity as a rate 0.18 mmol/h 
with [125I] insulin B-chain in sciatic nerves from rats without inflammation. In pig femoral nerve 
NEP activity was 3.7 mmol/h (Barnes et al., 1991). The two groups prove the activity with 
enzyme specific inhibitors phosphoramidon. Interestingly, our findings suggest that 
inflammation enhanced NEP activity (by 41%) in the sciatic nerve. The effects of injury on 
NEP activity in peripheral nerves have not been addressed so far. However, similar to our 
observations, NEP expression and activity was higher in wounded skin from diabetic patients 
compared to healthy controls (Antezana et al., 2002). An increase of peptidase activity in 
synovial fluid was also shown in chronic diseases such as rheumatoid arthritis in humans, 
which are characterized by an increase number of macrophages and mature lymphocytes 
(Spreedharan et al., 1990; Matucci-Cerinic et al., 1993; Simonini et al., 2005). In contrast to 
our observations, no differences of NEP activity were found in CNS of chronic arthritis 
compare to control rats (Van Veldhoven et al., 1982).  
We verified the specificity of NEP activity by showing that its selective inhibitor 
thiorphan dose-dependently and fully prevented the formation of pNA in vital immune cells 
(10 mM) and their membranes (1 µM) as well as in sciatic nerves (8 mM). Previously it was 
shown that thiorphan (10 - 100 µM) completely abolished the hydrolysis of Suc-Ala-Ala-Phe-
pNA in cultured and purified peripheral human T lymphocytes, and in human thymocytes 
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(Mari et al., 1992, 1994). Direct investigations of neutrophils and corresponding membranes 
observed 85% inhibition of NEP activity after treatment with 0.1 mM thiorphan (Marotti et al., 
2000; Balog et al., 2001). Those studies used immune cells from healthy donors, which might 
explain lower concentrations of thiorphan than in our experiments with leukocytes from 
inflamed tissue. Thiorphan-dependent activity has not been so far tested in peripheral nerves 
under pathological conditions, but it was observed in brain and spinal cord of healthy rodents 
(Florentin et al., 1984; Roques et al., 1993). Thus, our results suggest that NEP expressed in 
the CNS and in peripheral nerves are functionally similar.  
We also showed that the new dual APN and NEP inhibitor P8B fully prevented the 
NEP substrate degradation in immune cell membranes (1 µM) and in sciatic nerves (10 mM). 
Furthermore, the generation of pNA could be dose-dependently attenuated by about 42% by 
10 mM of P8B in vital immune cell assay and this attenuation was improved (reaching 64%) 
after decreasing the cell number by half. P8B was previously tested only by our corroborators 
who, using NEP purified from rabbit kidney and flourophore dansyl-Gly-(pNO2)-Phe-ßAla as 
NEP specific substrate, showed that P8B displayed a dissociation constant Ki value of 2.0 
nM, implying that the complex of enzyme-inhibitor is stable and therefore the affinity of the 
inhibitor to NEP is high. In addition, the affinity of P8B to another enzyme ACE was very low 
(Ki value of 2500 nM) confirming NEP selectivity of the inhibitor (Chen et al., 1998, 2000). A 
need for relatively high P8B doses in our experiments might be related to the use of nerves 
and vital immune cells as NEP source versus a purified NEP by Chen et al. (1998). 
In summary, we showed that NEP and APN cleave their specific substrates in 
immune cells and their membranes, and in the sciatic nerve terminal branches, suggesting 
that leukocytic and neuronal APN and NEP in inflamed painful tissue are functionally similar. 
This degradation was reversible by the respective peptidase specific inhibitors thiorphan and 
bestatin and by the new dual inhibitor P8B. 
 
 
4.3.  Effects of peptidase inhibitors on the levels of immune cell-derived 
enkephalins 
 
4.3.1 Degradation of immune cell-derived MENK and LENK 
 
Our group demonstrated that inflammatory pain can be decreased as a consequence 
of peripheral opioid receptor activation by MENK and END released from immune cells 
accumulating in inflamed tissue. Even though several studies examined the release of opioid 
peptides from immune cells, this was always done in the presence of peptidase inhibitors 
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(e.g. Rittner et al., 2006, 2009), and the functional relevance of leukocytic peptidases was 
not directly addressed so far. In the present study we found that immune cells isolated from 
CFA-inflamed rat paws released MENK and LENK as their extracellular levels were 
enhanced by 23 – 97.5 pg and 6 – 9.6 pg after 4 h of incubation in vitro, respectively. To 
further verify our results we examined whether the increased levels measured at 4 h were 
related to enkephalins or their metabolites. In previous studies that used HPLC, APN was 
shown to cleave MENK and LENK to its metabolites Tyr and Gly-Gly-Phe-Met, whereas NEP 
degraded both enkephalins to Tyr-Gly-Gly and Phe-Met (Venturelli et al., 1985; Giroset al., 
1986b; Shibanoki et al., 1992; Miller et al., 1994a). We tested some of the synthetic analogs 
of these metabolites and found that Abs used in our RIA measurements did not recognize 
Tyr-Gly-Gly-OH, Gly-Gly-Phe-Met-OH and Gly-Gly-Phe-Leu-OH, but selectively detected 
MENK or LENK. Thus, the increased extracellular levels of enkephalins at 4 h were obviously 
related to a continuous liberation of these peptides from the inflammatory cells. Prolongation 
of the cell incubation time to 8 h resulted in a significant drop of accumulated extracellular 
levels of MENK and LENK determined in the supernatant, reaching the basal levels (at 0 h). 
Relatively slow leukocyte-derived enkephalin degradation was surprising because it was 
investigated previously that enkephalins are susceptible to a rapid catabolism by APN and 
NEP. This has been predominantly shown for exogenously added enkephalins (7.4 – 64.8 
µM) to plasma from healthy humans or from rats and mice, and under these conditions full 
opioid peptide degradation (as assessed by the accumulation of their metabolites) was 
detected within minutes (Venturelli et al., 1985; Shibanoki et al., 1991, 1992). This quick 
degradation might have been related to an easier accessibility of peptidases by peptides 
when they were in high (micromolar) concentrations compared with the nanomolar range of 
MENK (2 nM) and LENK (0.23 nM) released from immune cells in our assays. Also the whole 
plasma as a cell mix was investigated, but there are some studies that investigated opioid 
peptide degradation by sorted immune cells. In murine macrophages and nylon wool-
enriched splenic T cells, exogenously added MENK (even in high concentration of 0.2 mM) 
was degraded at a rate of 11% per hour (Miller et al., 1994a,b). Also, in healthy rat 
splenocytes a hydrolysis rate of 8 – 18% of the total LENK and MENK amounts added was 
noted per hour (Amoscato et al., 1993). The above data are comparable with the enkephalin 
hydrolysis rate of 7.5 - 9% per hour in our immune cell assays. We could not observed 
differences in peptidase-induced metabolism between endogenous enkephalins in our 
assays and exogenously added enkephalins in the studies above. Furthermore, these data 
show that addition of high amounts of MENK is not accompanied by an increase in the 
hydrolysis rate. One reason might be that opioid peptides bind predominately to opioid 
receptors that are likewise expressed on immune cells. Opioids have a higher affinity to 
opioid receptors (nanomolar) compared to peptidases (micromolar) (Skidgel et al., 1984). 
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Taken together, MENK and LENK secreted by immune cells from painful inflamed 
tissue are degraded by leukocytic peptidases. These findings raised the question on the 
contribution of APN and NEP in this opioid peptide degradation and this question was 
addressed using peptidase-specific inhibitors. 
 
 
4.3.2 Effects of selective and dual APN and NEP inhibitors on the levels of 
immune cell-derived MENK and LENK 
 
Treatments with a combination of thiorphan and bestatin or P8B paradoxically 
significantly decreased MENK levels at 0 h and 4 h. A tendency of MENK accumulation over 
time in the inhibitor treated groups was found, while opioid levels decreased between 4 and 8 
h incubation time in the inhibitor-free samples. Similarly, accumulation of LENK became 
apparent in P8B-treated groups at 8 h. In this assays inhibitor treatment could not increased 
the enkephalin level compared to control group after 8 h and therefore our hypothesis could 
not be confirmed. In contrast, the levels of LENK were not affected at 0 - 4 h by a 
combination of thiorphan and bestatin. At the later stage of incubation (after 8 h), the 
prevention of LENK degradation was even more pronounced, resulting in an elevation of the 
peptide level by about 47% over the levels found in inhibitor-free groups. Moreover, LENK 
amount enhanced by about 13.5% compared to accumulated level at 4 h, which suggested 
that degradation of LENK could be displaced by immune cell released opioid peptides at 8 h. 
We can exclude that the inhibitors stimulate the release of LENK, because the peptide 
accumulation at 4 h was similar in inhibitor-treated and in the inhibitor-free control groups. 
These findings are in accordance with our hypothesis and verify it by showing that the 
combined treatment of immune cells with thiorphan and bestatin counteracts LENK 
degradation. At the moment, we could not solve our technical problems. Although inhibitors 
in these experiments were used in relatively high concentrations (1 – 5 mM), they were still 
lower than in experiments testing specific synthetic substrate degradation (5 – 20 mM). 
Adjustment of the doses was necessary to keep the immune cells viable, particularly when 
they were treated with bestatin and thiorphan at the same time. Although it was possible to 
use P8B in concentrations up to 20 mM, the concentration was matched to bestatin-
treatment in our immune cell assays. Even though the same concentrations of bestatin and 
thiorphan were used to study the degradation of the different opioid peptides, only the levels 
of MENK were affected by the inhibitors, while the degradation of LENK was prevented, and 
none of the inhibitors at any time significantly changed the levels of immune cell-derived 
DYN and END (see paragraph 4.6). Thus, it appears that in certain conditions APN and NEP 
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inhibitors interfered only with endogenous enkephalins. Possible reasons could be that 
inhibitors somehow interact with enkephalins in a way that they diminish the accessibility of 
primary RIA Abs to the peptide or that inhibitors decrease the secretion of enkephalins from 
leukocytes. The second possibility was previously indicated for MENK in rat striatum slices 
(De La Baume et al., 1983). 
Only few studies have previously examined opioid peptide hydrolysis using immune 
cells and all of them used leukocytes from healthy animals and exogenously applied 
enkephalins. In 1994 the group of Miller and colleagues demonstrated MENK catabolism in 
the presence of macrophages and spleen lymphocytes isolated from pathogen-free mice. 
Degradation of MENK was attenuated (by 50 – 60%) by treatment with bestatin (10 µM) and 
another APN selective inhibitor amastatin (10 – 200 µM) (Miller et al., 1994a, b). In rat 
splenocytes and natural killer cells the catabolism of MENK and LENK was decreased by 85 
- 96% by bestatin (1 mM) (Amoscato et al., 1993). Also, hydrolysis of MENK and LENK in rat 
plasma was inhibited with bestatin (500 µM) and thiorphan (100 µM), although the cellular 
source of the peptidases was not identified (Shibanoki et al., 1991). In summary, none of the 
previous studies examined the impact of APN and NEP degradation of immune cell-derived 
opioid peptides in a pathological situation. 
Our findings indicate that under painful inflammatory conditions immune cell-derived 
enkephalins are slowly degraded by peptidases expressed on the surface of intact 
leukocytes in vitro. This does not result from inactive peptidases because they were capable 
to degrade other substrates (Ala-βNA and Suc-Ala-Ala-Phe-pNA; see paragraph 4.2). Due to 
the unexpected effects of APN and NEP inhibitors on the levels of immune cell-derived 




4.4. Enkephalin degradation and its prevention in immune cell membranes 
 
In immune cell membrane suspensions APN and NEP were functional because they 
cleaved their specific substrates (see paragraphs 4.2.1 and 4.2.2). Now we found that the 
levels of exogenously added MENK and LENK were substantially lower (by 47 - 70% and 
77%, respectively) following 4 h incubation with immune cell membranes. The hydrolysis rate 
of enkephalins in membrane assays was 12% - 19% per hour. It seems, that degradation 
rate depend on tissue preparation type, which was found previously by groups of De la 
Baume (1983) and Chaillet (1983). They observed that metabolic pattern depends on the 
type of tissue preparation, for example accumulations of metabolites were higher in the brain 
membrane fractions compared to brain slices. 
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The low levels of enkephalins resulted from the action of APN and NEP because the 
degradation of MENK and LENK was dose-dependently and fully prevented by a 
combination of thiorphan and bestatin and by P8B. The interference of the inhibitors was 
obvious only when endogenous MENK was analyzed. Our findings indicate that MENK and 
LENK are targets for leukocytic APN and NEP in immune cell membrane preparations. So far 
there are no studies, which observed explicitly the effect of the novel inhibitor P8B on 
prevention of opioid peptide degradation. Also, similar experiments using membranes of 
leukocytes have not been performed previously. Nevertheless, our findings are in line with 
the studies reporting the APN- and NEP-dependent cleavage of exogenous enkephalins in 
intact immune cell suspensions or plasma (Venturelli et al., 1985; Giros al., 1986b; Shibanoki 
et al., 1992; Amoscato et al., 1993; Miller et al., 1994a, b) as discussed in detail above (see 
paragraph 4.3.). Concentrations of bestatin (5 µM - 0.5 mM) and thiorphan (1 µM - 0.1 mM) 
used in our experiments are similar to those used in the studies mentioned above using cells 
from healthy animals. All these studies used exogenously applied enkephalins and did not 
found interferences with the inhibitors, like we see in our immune cell membrane and control 
experiments with synthetic opioid peptides. Also, they used HPLC as a method to detecting 
the metabolites of enkephalin degradation, which in contrast to our RIA worked without Ab 
accessibility.  
Taken together, in our model of CFA induced painful inflammation we could show that 
APN and NEP expressed on immune cells induced degradation of enkephalins. Importantly, 
enkephalin degradation can be fully blocked with both classical selective (thiorphan and 
bestatin) and novel dual (P8B) APN and NEP inhibitors. These results show that immune 
cells are a source to degrade opioid peptides in painful inflamed tissue, but also peripheral 
neurons could be a source of APN and NEP activity on opioid peptide degradation.  
 
 
4.5. Enkephalin degradation and its prevention by blockade of APN and NEP 
in peripheral nerves  
 
Here, the impact of peripheral neuronal APN and NEP on opioid peptide degradation 
in pathological situation was examined. We found that both peptidases on terminal branches 
of the sciatic nerve innervating such tissue are functional by means of specific synthetic 
substrate degradation (see paragraph 4.2.). In these experiments we demonstrated that 
levels of exogenously applied MENK and LENK were diminished by 78 - 85% and 79 - 88%, 
respectively, after 4 h incubation. Notably, neuronal APN and NEP mediated enkephalin 
degradation as documented by its dose-dependent and full inhibition by a combination of 
thiorphan (5 mM) and bestatin (10 mM) or by P8B ( 1 – 10 mM). Previous studies examining 
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a role of APN and NEP in degradation of opioid peptides were performed exclusively in the 
CNS. Hydrolysis of exogenous [3H]LENK was inhibit by thiorphan (1 – 100 nM) in mouse 
striatum fraction (Roques et al., 1980). Also, hydrolysis of endogenous MENK released from 
rat striatum slices was prevented in the presence of 0.1 µM thiorphan (Patey et al., 1981). 
Further investigation in rat striatum slices examined the metabolite formation after [3H]MENK 
degradation was inhibited by 40% in the presence of 20 µM bestatin and 29% by 0.1 µM 
thiorphan and the co-presence of both selective inhibitors resulted in total recovery of the 
enkephalin in the medium (De la Baume et al., 1983). This was supported by another study 
showing that bestatin (0.1 mM) or thiorphan (0.2 µM) used separately attenuated [3H]MENK 
metabolism by 13% and 59%, respectively, while their combination decreased the hydrolysis 
by 76% in rat globus pallidus slices (Giros et al., 1986a). None of those previous studies 
examined inhibitors in a dose-dependent fashion and it seems that blockade of peptidase 
activity depend on the neuronal region. Also, concentrations of bestatin and thiorphan used 
in those studies were lower than in our assays (5 - 10 mM). This could be related to the use 
of CNS tissues from healthy animals in the other studies versus peripheral nerves from 
inflamed tissue in our experiments. Another study also showed the importance of a 
concomitant APN and NEP blockade. A clear protection (by 85%) of [3H]MENK degradation 
by treatment with a combination of thiorphan (1 µM) and bestatin (20 µM) was reported in 
slices from rat spinal cord, while the inhibitors were inactive when applied separately. 
Moreover, this group investigated kelatorphan, one of the first dual inhibitors, which 
completely prevented the degradation of exogenously added [3H]MENK as well as of 
endogenous MENK released from spinal cord slices (Bourgoin  et al., 1986). Regarding dual 
APN and NEP inhibitors, in none of the previous studies P8B was used and effects of all 
other dual inhibitors on enkephalin degradation was tested only in the CNS. A couple of 
studies showed similar effects in vivo using microdialysis in the CNS, in awake and freely 
moving rats. One of them reported that systemic (i.p.) injection of another dual inhibitor 
RB101 increased extracellular levels of MENK in the nucleus accumbens (Dauge et al., 
1996). The other found increased extracellular levels of MENK in the periaqueductal gray 
after i.p. administration of aminophosphinic inhibitor RB3007 (Le Guen et al, 2003). 
Summing up, our current findings substantially expand earlier studies performed in 
the CNS of healthy animals, by demonstrating that classical selective and a novel dual 
inhibitor can block APN and NEP on peripheral nerves innervating painful inflamed tissue 
and protect MENK and LENK from the degradation. 
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4.6. Effect of peptidase inhibitors on the levels of DYN and END  
 
In this study MENK and LENK came out as targets for leukocytic and neuronal APN 
and NEP, but in addition to enkephalins, leukocytes infiltrating inflamed tissues also contain 
DYN and END which contribute to the local pain inhibition (reviewed in Machelska, 2007; 
Busch-Dienstfertig and Stein, 2010). These opioid peptides have longer sequences of 17 
amino acids (DYN) to 31 amino acids (END) and the question arose whether these opioid 
peptides are also targets for APN and NEP in our model of CFA induced inflammation. In the 
current study, immune cells from inflamed rat paws secreted DYN and END and their 
extracellular levels were elevated by 43 - 58% and 53 - 68%, respectively, over 8 h of 
incubation in vitro. Thus, it appears that leukocyte-derived DYN and END are not or less then 
liberated opioid peptides hydrolyzed by peptidases in intact immune cells. However, in 
immune cell membrane suspensions we observed a degradation of exogenously applied 
DYN (by 47%) and END (by 37 - 39%). Treatment with a combination of thiorphan and 
bestatin or with P8B, in doses which blocked the degradation of MENK and LENK, did not 
prevent the catabolism of DYN and END in immune cell membranes. In peripheral nerve 
preparations from inflamed rat hind paw, exogenous END were catabolized by 74 - 83% and 
treatment with inhibitors did not affect END level. A possible explanation could be that the 
degradation of DYN and END in our assays is done by other zinc metallopeptidases, which 
are not sensitive to the inhibitors. For example, both opioid peptides has been shown to be 
cleave by γ-endorphin-generating enzyme, which is mostly located in cytosol, peroxisomes 
and in a low level in plasma membrane of enterocytes and immune cells (Safavi et al., 1996; 
Song ES et al., 2003). It was examined, that END cleavage by γ-endorphin-generating 
enzyme has been measured only after differentiation of the cells in activated mouse 
macrophages and T cells (Thiele et al., 1998), which correspond with the cells taken from 
inflamed tissue. The hydrolysis of DYN and END was only evaluated in leukocytic membrane 
assays, which my explained by low expression of γ-endorphin-generating enzyme in plasma 
membranes and it is difficult to ascertain whether membranes, even when washed, are not 
contaminated by cytosolic peptidases.  
Furthermore, we found that exogenous DYN was catabolized by 46 - 57% in 
peripheral nerve branches from inflamed rat paws. Treatment with high concentrations of 
inhibitors prevented the hydrolysis of DYN increasing 1.9 – 2.4-fold its levels over basal (0 h) 
concentrations of exogenously applied DYN. This suggests that inhibitors might have 
prevented the degradation of endogenous DYN previously detected in primary afferents in 
inflamed rat paws (Hassan et al., 1992). Thus, our present findings identify DYN as a 
substrate of neuronal APN and NEP in inflammation, suggesting a tissue dependent activity 
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of both peptidases on opioid peptide degradation. The role of APN and NEP in degradation 
of DYN has been not investigated in peripheral neuronal tissue so far. Previous studies were 
performed mostly with purified APN and NEP from kidney. In a study by Hersh (1984) 
kinetics of opioid peptide degradation by NEP from human and rat kidney and rat brain were 
investigated. It was found that DYN and END are poor substrates for NEP in contrast to 
MENK and LENK. Similarly, 100 times more purified kidney NEP was needed for hydrolysis 
of END compared with enkephalins (Graf et al., 1985). Also, Safavi and colleagues (1995) 
found DYN degradation by purified APN from rat kidney, but the hydrolysis rate is 70 fold 
lower compared to LENK. Taken together, they all demonstrated that when length of the 
substrate increases, the affinity of the substrate to the peptidase decreases.  
In summary, in our model of peripheral painful inflammation the degradation of END 
could not blocked with inhibitors, which eliminate this opioid peptide as a substrate for 
leukocytic and neuronal APN and NEP. DYN came out as substrate for neuronal APN and 
NEP. This degradation was reversible by the specific inhibitors thiorphan and bestatin and by 
the new dual inhibitor P8B.  
 
 
4.7. Analgesic effects of APN and NEP inhibitors 
 
We followed our in vitro findings on leukocytic and neuronal APN and NEP activity in 
opioid peptide degradation and its prevention with enzyme specific inhibitors by in vivo 
investigations. Injection of a combination of thiorphan and bestatin or of P8B directly into 
inflamed rat paws led to amelioration of pain measured with the paw pressure test. These 
antinociceptive actions were fully reversed by co-injected Abs against MENK, LENK or DYN, 
and were slightly decreased by anti-END. This suggests that pain-attenuating effects of APN 
and NEP inhibitors resulted from preventing predominately enkephalins and DYN from the 
degradation in peripheral inflamed tissue, corroborating our in vitro findings in immune cells 
and peripheral nerves. This is supported by a study which addressed the degradation of 
exogenously applied MENK, LENK and DYN examining their ability to internalize µ-opioid 
receptors in spinal cord slices. These authors found that µ-opioid receptor internalization was 
induced by a mixture of inhibitors of APN and NEP and of another peptidase, dipeptidyl 
carboxypeptidase. END-mediated µ-opioid receptor internalization was independent of APN 
and NEP in that study (Song and Marvizon, 2003). In contrast to our in vitro findings we 
observed a decreased analgesic effect after anti-END Abs injection. This may explained by a 
blockade of APN and NEP expressed on other tissues such as fibroblasts and endothelia 
cells (Shipp and Look, 1993; Mina-Osario, 2008). Another study describes some remaining 
analgesic effects of RB101 in ENK-KO mice. Although they do not test the nature of this 
______________________________________________________________________________________________________________
 Discussion 
  62 
remaining analgesia, this suggests that it is mediated by other opioids than enkephalins such 
as END and endomorphins (Noble et al., 2008). In previous behavioral investigations, only 
one study tested APN and NEP inhibitors in peripheral inflamed tissue. Thus, a combined 
i.pl. injection of thiorphan (0.2 mg) and bestatin (0.2 mg) prolonged stress-induced 
antinociception mediated by endogenous opioids, but did not change basal nociceptive 
thresholds in inflamed paws (Parson and Herz, 1990). This was probably due to insufficient 
dosing of inhibitors, as in our current studies to obtain substantial peripheral antinociception 
thiorphan and bestatin required higher doses (0.8 mg and 5 mg, respectively). Most earlier 
studies showed antinociceptive effects of selective ANP and NEP inhibitors following 
systemic or into the CNS structures injections in healthy mice and rats. A moderate 
potentiation of antinociception after i.c.v. injected dynorphin B or END by pretreatment with 
thiorphan or bestatin was found in acute pain models (Roques et al., 1980; Chaillet et al., 
1983; Nakazawa et al., 1989; Suh et al., 1990). Combined i.c.v. application of both inhibitors 
elevated thresholds to thermal stimulation in mice and rats, which was reversible by 
naloxone, an opioid receptor antagonist (Carenzi et al., 1983). Furthermore, few clinical 
studies showed that i.v. injections of thiorphan or its prodrug acetorphan decreased NEP 
activity in plasma and cerebrospinal fluid and produced some analgesia in selected number 
of patients with migraine or after myelography (Floras et al., 1983; Spillantini et al., 1986). In 
cancer pain patients a combination of adjuvant with bestatin attenuated recurrence of 
bladder cancer (Uchibayashi et al., 1995). Also, bestatin and thiorphan applied concomitantly 
on the spinal cord produced significant pain inhibition in cancer patients (Meynadier et al., 
1988). Our current results might have clinical implications for treatment of inflammatory pain 
such as arthritis. 
Dual APN and NEP inhibitors have not been examined in clinical situation so far. In 
healthy rodents the antinociceptive effect of MENK was potentiated by i.c.v. co-administrated 
kelatorphan (Fournie-Zaluski et al., 1984). Intravenous injection of RB101 induced dose-
dependent and naloxone-reversible antinociceptive responses in thermal acute pain tests in 
wild type mice (Noble et al., 1992) and these effects were much weaker in preproenkephalin-
deficient mice in tests employing noxious mechanical, thermal and chemical stimulation 
(Noble et al., 2008). Also, aminophosphinic dual inhibitor RB3007 injected i.v. decreased in a 
naloxone-sensitive manner the sensitivity to acute thermal, chemical and mechanical stimuli 
as well as nociceptive behaviors in a formalin-induced tonic pain in mice (Le Guen et al., 
2003). The only two studies assessing APN and NEP dual inhibitors in prolonged 
inflammatory pain reported naloxone-reversible antinociceptive effects following i.v. injection 
of RB101 and RB3007 in the CFA inflammatory model (Maldonado et al., 1994; Le Guen et 
al., 2003). P8B was only reported to produce antinociception after i.c.v. injection in acute 
thermal pain in mice without tissue injury (Chen et al., 1998, 2000). 
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Taken together our studies substantially extend previous reports which showed 
antinociceptive effects of APN and NEP inhibitors mostly in acute animal pain models 
following central and systemic injections. All previous studies showing only involvement of 
MENK and opioid receptors tested with a non-selective antagonist naloxone were addressed. 
Our data clearly show that simultaneous application of bestatin and thiorphan or P8B 
produced substantial antinociception against noxious pressure in a model of prolonged 
inflammatory pain. This effect was reversed by Abs against MENK, LENK and DYN and was 
slightly attenuated by anti-END. Based on our in vitro findings, the pain ameliorating actions 
were most likely mediated by enhanced levels of endogenous enkephalins and DYN as a 
consequence of the blockade of APN and NEP in leukocytes and peripheral nerves.  
 
 
4.8. Future studies 
 
In the present study we have characterized the expression and activity of APN and 
NEP in leukocytes and peripheral endings of sensory neurons in painful inflamed tissue. 
Using classical selective (thiorphan and bestatin) and a novel dual (P8B) inhibitors we 
comprehensively investigated the effects of leukocytic and neuronal APN and NEP on the 
degradation of four opioid peptides MENK, LENK, DYN and END. In immune cell 
membranes and sciatic nerves we consistently showed that degradation of MENK and 
LENK, but not of END, was fully prevented by the inhibitors, pointing to enkephalins as main 
targets of leukocytic and neuronal APN and NEP. In addition, DYN appeared the substrate of 
APN and NEP on peripheral nerves. However, in vital immune cells MENK levels were 
paradoxically diminished by selective and dual APN and NEP inhibitors, while LENK levels 
were decreased by the dual inhibitor. Although to examine opioid levels inhibitors were used 
in relatively high concentrations (1 – 5 mM), they did not affect immune cell viability. 
Nevertheless, they might have affected enkephalin level measurements. An alternative to 
synthetic peptidase inhibitors might be their endogenous counterparts, which could be tested 
in future investigations. A possible candidate is sialorphin, which is synthesized 
predominantly in submandibular gland and prostate of adult rats in response to androgen 
steroids and is released locally and into the bloodstream in response to environmental 
stress. Sialorphin was characterized as inhibitor of renal and CNS NEP and was able to 
prevent the degradation of MENK in vitro (Rougeot et al., 2003). Opiorphin is another potent 
endogenous APN and NEP inhibitor recently identified in human saliva. In human cell line 
experiments opiorphin prevented the degradation of APN and NEP specific substrates as 
well as of MENK (Wisner et al., 2006). Both inhibitors injected systemically (i.v. or i.p.)  
______________________________________________________________________________________________________________
 Discussion 
  64 
 
elicited opioid receptor-mediated antinociception in rat models of acute and formalin-induced 
pain (Rougeot et al., 2003; Wisner et al., 2006).  
Another attractive approach to suppress the expression and function of both 
peptidases is the use of siRNA. Silencing of APN expression by siRNA markedly decreased 
the migration and proliferation of ovarian carcinoma cells and attenuated enzymatic activity 
of APN in osteosarcoma cell line (Kido et al., 2003; Terauchi et al., 2007). It would be 
interesting to explore whether silencing of APN and NEP by siRNAs in immune cells has 
more favorable effects on the levels of enkephalins than synthetic inhibitors and whether it 
results in the inhibition of pathological pain.  
In the literature it is described that both metallopeptidases cleave certain chemokines 
(CXCL8, CXCL11/12, fMLP), while NEP can degrade substance P and bradykinin, which are 
pro-nociceptive and pro-inflammatory mediators (Roques et al., 1993; Ramirez-Molina et al., 
2006; Turner et al., 1997; Mina-Osorio, 2008). However, these effects were described 
exclusively in vitro and do not seem to influence pain perception in vivo. This is supported by 
numerous in vivo studies showing exclusively antinociceptive actions of APN and NEP 
inhibitors injected systemically or into the CNS structures (see paragraph 4.5) as well as by 
our current studies showing that thiorphan and bestatin and P8B clearly produced 
antinociception in inflamed paws. No involvement of interactions between APN, NEP and 
substance P in nociception might be attributed to sequestration and predominant degradation 
of substance P by its own metabolizing peptidases that are not sensitive to NEP inhibitors 
(Rougeot et al., 2003). Furthermore, substance P and bradykinin were described as natural 
inhibitors of APN, as both compounds inhibited the enzyme activity in assays using Ala-βNA 
or LENK as substrates. Interestingly, substance P was as potent as bestatin in blocking APN 
(Xu et al., 1995). Moreover, peripherally acting opioids can inhibit the release of substance P 
from peripheral terminals of primary afferent neurons (Yaksh, 1988) and to block the 
synthesis of cytokines in macrophages (Belkowski et al., 1995). On the other hand, APN was 
found to possess chemotactic properties. In patients with rheumatoid arthritis APN 
participated in lymphocytic infiltration of the synovial fluid, which was partially inhibited by 
bestatin (Shimizu et al., 2002). Although there is no doubt about pain-relieving actions of 
APN and NEP inhibitors, it would still be interesting to examine their effects on the migration 
of immune cells containing opioid peptides and on the levels of opioid peptides and 
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5. Summary 
 
Opioids are used as pharmacological treatment of severe acute and chronic pain 
states. However, their actions are associated with side effects such as nausea, depression of 
breathing, physical dependence and addiction that result from the activation of opioid 
receptors in the central nervous system (CNS). In contrast opioid peptides produced 
naturally in the body control pain without eliciting CNS side effects. In inflammation, immune 
cells infiltrate the site of injury or infection and liberating opioid peptides. The released 
opioids bind to opioid receptors on peripheral sensory nerves resulting in the inhibition of 
inflammatory pain. Nevertheless, opioid peptides are susceptible to enzymatic inactivation. 
The degradation of opioids by peptidases such as aminopeptidase N (APN) and neutral 
endopeptidase (NEP) has been extensively examined in the CNS and immune cells from 
healthy animals and humans. Our hypothesis in the current study is that the blockade of 
opioid-metabolizing peptidases APN and NEP expressed on immune cells and peripheral 
nerves in inflamed tissue prevents opioid peptide degradation and ameliorates inflammatory 
pain. As a model of such condition we employed complete Freund’s adjuvant-induced 
unilateral hind paw inflammation in rats and we investigated degradation of all four opioid 
peptides i.e. Met-enkephalin (MENK), Leu-enkephalin (LENK), dynorphin A (DYN) and β–
endorphin (END). To assess enzymatic selectivity of opioid degradation we used bestatin 
and thiorphan to selectively block APN and NEP, respectively, as well as a novel inhibitor 
P8B that is equally selective for both peptidases. Using flow cytometry we detected APN and 
NEP on macrophages and granulocytes, but not on T lymphocytes from inflamed rat hind 
paws. The activity of leukocytic and neuronal APN and NEP was determined 
photospectrometrically as their ability to degrade their specific synthetic substrates Alanin-ß-
naphthylamine (Ala-βNA) and Succinyl-alanin-alanin-phenylalanine-p-nitroaniline (Suc-Ala-
Ala-Phe-p-NA), respectively. In vitro incubation of these substrates with vital immune cells, 
immune cell membranes or sciatic nerve suspensions led to accumulation of the metabolites 
βNA and pNA, indicating APN and NEP activity, respectively. The degradation of the 
peptidase-specific substrates was dose-dependently prevented with bestatin, thiorphan, and 
P8B in all three tissues preparations, suggesting that leukocytic and neuronal APN and NEP 
are functionally similar. Degradation of immune cell-derived MENK and LENK, but not of 
DYN and END, was observed between 4 h and 8 h of cell incubation, as reflected by a 
decrease of the extracellular peptide levels over time measured with radioimmunoassay. 
Unexpectedly, treatment with thiorphan and bestatin or with P8B significantly decreased the 
levels of MENK. In contrast inhibitor-induced prevention of LENK degradation could show at 
8 h. In immune cell membranes or sciatic nerve suspensions the amounts of exogenously  
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applied MENK, LENK, DYN and END significantly dropped within 4 h of incubation. In both 
tissue preparations, the catabolism of MENK and LENK, but not of END, was dose-
dependently and fully prevented with a combination of bestatin and thiorphan or with P8B 
alone. This shows that both enkephalins are important substrates of leukocytic and neuronal 
APN and NEP in peripheral inflamed tissue. Selective and dual inhibitors prevented the 
degradation of DYN in suspensions of the sciatic nerves, but not in immune cell membranes. 
This indicates that under inflammatory conditions DYN becomes a substrate of APN and 
NEP on peripheral nerves. Finally, concomitant injection of thiorphan and bestatin or of P8B 
into inflamed rat paws decreased inflammatory pain in response to noxious pressure in vivo. 
These antinociceptive effects were completely reversed by co-injected Abs against MENK, 
LENK and DYN, and were only slightly attenuated by anti-END.  
In conclusion, blockade of ANP and NEP expressed on leukocytes and peripheral 
nerves from inflamed painful tissue prevented the degradation of enkephalins or DYN, and 
ameliorated inflammatory pain. These results provide a rationale for a promising strategy for 
pain control based on the enhancement of the analgesic actions of endogenous opioid 
peptides by inhibiting their enzymatic degradation directly in injured tissues. Thus, a 
combination of classical selective inhibitors bestatin (APN) and thiorphan (NEP) as well as 
the novel dual inhibitor P8B might represent a new class of analgesics without the untoward 
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Zusammenfassung 
 
Zur pharmakologischen Behandlung bei diversen akuten und chronischen Schmerzen 
werden unter anderem Opioide eingesetzt, allerdings führt dieser Einsatz auch zu 
ungewollten Nebeneffekten wie Übelkeit, Atemstillstand und Drogenabhängigkeit, welche 
durch die Aktivierung von Opioidrezeptoren im Zentralen Nervensystem (ZNS) ausgelöst 
werden. Im Gegensatz dazu führen körpereigene Opioidpeptide zur Schmerzlinderung ohne 
zentral ausgelöste Nebenwirkungen zu verursachen. Bei schmerzhaften entzündlichen 
Erkrankungen infiltrieren Immunzellen das betroffene Gewebe und setzen endogene 
Opioidpeptide frei, welche an Opioidrezeptoren auf peripheren sensorischen Nerven binden 
und dort die Schmerzübertragung verhindern. Allerdings werden Opioidpeptide durch 
Peptidasen wie Aminopeptidase N (APN) und Neutrale Endopeptidase (NEP) abgebaut, was 
intensiv im Zentralen Nervensystem und an Immunzellen von gesunden Tieren und 
Menschen untersucht wurde. Die Hypothese der hier durchgeführten Studie ist, durch 
Inhibierung der opioid-abbauenden Peptidasen APN und NEP den Abbau von 
Opioidpeptiden zu verhindern, wodurch sich die endogen vermittelte Linderung von 
Entzündungsschmerz verbessert. Als Entzündungsmodell wurde die Freund`s Complete 
Adjuvants-induzierte, lokale Entzündung einer Hinterpfote bei Ratten angewandt, um die 
Wirkung der selektiven Inhibitoren Bestatin (APN) und Thiorphan (NEP), sowie des 
neuartigen Dualen-Inhibitor P8B auf die Degradation der vier Opioidpeptide Met-Enkephalin 
(MENK), Leu-Enkephalin (LENK), Dynorphin A (DYN) und Endorphin (END) unter 
entzündlichen Bedingungen zu untersuchen. Mit Hilfe der Durchflusszytometrie konnten APN 
und NEP in der aus lokalen Entzündung entnommenen Makrophagen und Granulozyten, 
aber nicht auf T-Lymphozyten, nachgewiesen werden. Die Aktivität der leukozytären und 
neuronalen Enzyme APN und NEP wurde spektrophotometrisch anhand der Degradation 
enzym-spezifischer Substrate Alanin-ß-naphthylamine (Ala-βNA) und Succinyl-alanin-alanin-
phenylalanine-p-nitroaniline (Suc-Ala-Ala-Phe-p-NA) untersucht. Nach in vitro Inkubation 
dieser Substrate mit vitalen Immunzellen, Immunzellmembranen oder Nervengewebe-
Suspensionen kam es zur Akkumulation der entsprechenden Metaboliten βNA und pNA 
nach APN respektive NEP Aktivität. Die Degradation der enzym-spezifischen Substrate 
konnte dosis-abhängig durch Bestatin und Thiorphan oder P8B in den drei 
Gewebepräparationen verringert werden, was auf eine identische Funktion der leukozytären 
und neuronalen Enzyme APN und NEP hinweist. Die radioimmunologische Analyse von aus 
Entzündungszellen freigesetzten MENK und LENK zeigte, dass die Peptidmengen im 
extrazellulären Medium innerhalb der ersten vier Inkubationsstunden akkumulierten; im 
Laufe der folgenden 4 h wurden diese Peptide degradiert während sich die Akkumulation von 
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DYN und END über 8 h fortsetzte. Die Behandlung mit Bestatin und Thiorphan in 
Kombination oder P8B verringerte signifikant die Menge von MENK, was nicht erwartet 
wurde. Im Gegensatz dazu konnte der Abbau von Immunzell-freigesetzten LENK durch die 
kombinierte Gabe von Bestatin und Thiorphan nach 8 h signifikant inhibiert werden. Die 
Untersuchung des Abbaus von exogen zugegebenen Opioidpeptiden (MENK, LENK, DYN 
und END) an isolierten Immunzellmembranen und Suspensionen des Nervus ischiadicus aus 
entzündetem Gewebe zeigte, dass alle Peptide über einen Zeitraum von 4 h abgebaut 
wurden. Der Abbau von MENK und LENK, nicht aber der von END, wurde dosis-abhängig 
und vollständig durch Bestatin und Thiorphan oder P8B verhindert. Das bedeutet, dass beide 
Enkephaline wichtige Substrate für die leukozytären und neuronalen Enzyme APN und NEP 
in peripherem, entzündeten Gewebe sind. Dem Abbau von DYN konnte durch den Einsatz 
der Inhibitoren vor allem in Suspensionen vom Nervus ischiadicus, aber nicht an isolierten 
Immunzellmembranen, entgegengewirkt werden. Das lässt den Schluss zu, dass DYN als 
Substrat von neuronalen Enzymen APN und NEP bevorzugt wird. Diese in vitro Befunde 
werden durch unsere in vivo Untersuchungen gestützt. Hier resultierte die Injektion von 
Bestatin und Thiorphan in Kombination bzw. von P8B in das entzündete Pfotengewebe in 
einer erheblichen Verminderung der Hyperalgesie als Antwort auf einen schmerzhaften 
Druckreiz. Dieser analgetische Effekt der Inhibitoren, wurde durch die Gabe von spezifischen 
MENK-, LENK- und DYN-Antikörpern vollständig aufgehoben, die Injektion von END-
Antikörpern zeigte einen geringen Einfluss. 
Zusammenfassend ist festzustellen, dass im Rahmen der durchgeführten 
Untersuchungen der Abbau von Enkephalinen und DYN durch die Blockade von APN und 
NEP in Immunzellen und peripheren Nerven aus entzündetem schmerzhaftem Gewebe 
verhindert werden konnte, was zur Schmerzverminderung führte. Basierend auf der 
Erhöhung der Aktivität endogener Opioidpeptide durch Inhibierung des enzymatischen 
Abbaus im entzündeten Gewebe zeigen diese Ergebnisse eine mögliche Strategie zur 
Schmerzkontrolle auf. Deshalb könnten die klassischen selektiven Inhibitoren Bestatin (APN) 
und Thiorphan (NEP) oder der neue Duale-Inhibitor P8B eine neue Klasse von Analgetika 
repräsentieren, deren Anwendung keine der Nebenwirkungen von konventionellen 
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Appendix: Locations of companies and distributors 
 
Table A.1: Companies and distributors 
Company City Country 
Abbott Wiesbaden Germany 
Amersham Buckinghamshire UK 
Bachem Weil am Rhein Germany 
Bachem/Peninsula Laboratories Belmont, CA USA 
BD Bioscience  Heidelberg Germany 
Biochrom Berlin Germany 
Brand Wertheim Germany 
Callbiochem La Jolla, CA USA 
Carl Zeiss Mikroskopie Göttingen Germany 
Eastman Kodak Company Rochester, NY USA 
Eppendorf Hamburg Germany 
Falcon Heidelberg Germany 
GIBCO Invitrogen Corporation Karlsruhe Germany 
Kendro Osterode Germany 
Life Technologies Carlsbad, CA USA 
Millipore GmbH Eschborn Germany 
Parmingen/Becton Dickinson Heidelberg  Germany 
Pharmaleads Paris France 
Phoenix Laboratories Belmont, CA USA 
Santa Cruz Biotechnology Heidelberg Germany 
Serotec Oxford UK 
Shimadzu Europa GmbH Duisburg Germany 
Sigma-Aldrich Taufkirchen Germany 
Wallac Distribution GmbH Freiburg Germany 
Ugo Basile Comerio Italy 
 
